1 **Paramyxovirus matrix proteins modulate host cell translation via exon-junction**
2 **complex interactions in the cytoplasm**
3

4 Chuan-Tien Hung[1], Griffin D Haas[1], Ruth E Watkinson[1], Hsin-Ping Chiu[1], Shreyas Kowdle[1],
5 Christian S Stevens[1], Arnold Park[1], James A Wohlschlegel[2], Patricia A Thibault[1],
6 Benhur Lee[1,*]
7

8   1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
9   10029, USA
10   2. Department of Biological Chemistry, David Geffen School of Medicine, University of
11   California Los Angeles, Los Angeles, CA 90095, USA
12   3. Lead contact
13

14 * Correspondence: benhur.lee@mssm.edu
15

16 **ABSTRACT**

17 Viruses have evolved myriad strategies to exploit the translation machinery of host cells to
18 potentiate their replication. However, how paramyxovirus (PMVs) modulate cellular
19 translation for their own benefit has not been systematically examined. Utilizing
20 puromycylation labeling, overexpression of individual viral genes, and infection with wild-type
21 virus versus its gene-deleted counterpart, we found that PMVs significantly inhibit host cells'
22 nascent peptide synthesis during infection, with the viral matrix being the primary contributor
23 to this effect. Using the rNiV-NPL replicon system, we discovered that the viral matrix
24 enhances viral protein translation without affecting viral mRNA transcription and suppresses
25 host protein expression at the translational level. Polysome profile analysis revealed that the
26 HPIV3 matrix promotes the association of viral mRNAs with ribosomes, thereby enhancing
27 their translation efficiency during infection. Intriguingly, our NiV-Matrix interactome identified
28 the core exon-junction complex (cEJC), critical for mRNA biogenesis, as a significant
29 component that interacts with the paramyxoviral matrix predominantly in the cytoplasm.
30 siRNA knockdown of eIF4AIII simulated the restriction of cellular functions by the viral matrix,
31 leading to enhanced viral gene translation and a reduction in host protein synthesis. Moreover,
32 siRNA depletion of cEJC resulted in a 2-3 log enhancement in infectious virus titer for various
33 PMVs but not SARS-CoV-2, enterovirus D68, or influenza virus. Our findings characterize a
34 host translational interference mechanism mediated by viral matrix and host cEJC interactions.
35 We propose that the PMV matrix redirects ribosomes to translate viral mRNAs at the expense

36   of host cell transcripts, enhancing viral replication, and thereby enhancing viral replication.

37   These insights provide a deeper understanding of the molecular interactions between

38   paramyxoviruses and host cells, highlighting potential targets for antiviral strategies.

39

40   **KEYWORDS:** Paramyxovirus, matrix, exon junction complex, translation

INTRODUCTION

Human parainfluenza virus type 3 is a member of the *Paramyxoviridae*[1,2], a family of RNA viruses that includes pathogens of agricultural and global health importance such as Nipah virus (NiV), mumps virus, measles virus (MeV) and Newcastle disease virus (NDV)[1]. As a prominent respiratory tract pathogen, HPIV3 is a leading cause of various airway diseases, including pneumonia, croup, and bronchiolitis, with a notably high incidence in infants and young children [3-7]. HPIV3 is characterized by a negative-stranded RNA genome encapsulated within a lipid envelope, which is derived from the host cell membrane. The genome encodes six principal genes: nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), attachment (HN) proteins, and polymerase (L)[1,2].

Paramyxoviruses (PMVs) are classic cytoplasmic replicating viruses, and the progeny virions are released from the plasma membrane of the host cell. Viral assembly and budding are orchestrated by the matrix protein (M), a major structural protein underlying the viral envelope[8-10]. Despite their cytoplasmic life cycle, paramyxoviral M proteins from diverse genera, including those from Nipah (NiV-M), Hendra (HeV-M), Ghana (GhV-M) and Cedar (CedV-M) viruses (genus *Henipavirus*), Sendai virus (SeV-M, genus *Respirovirus*), mumps virus (MuV-M, genus *Orthorubulavirus*) and Newcastle disease virus (NDV-M, genus *Orthoavulavirus*), exhibit nuclear-cytoplasmic trafficking that is essential for matrix function[11-22]. Notably, these proteins can be detected in the nucleus during the early stages of infection[16]. Furthermore, NiV-M and HPIV3-M have been shown to counteract antiviral Type I interferon through RIG- or mitophagy-mediated pathways, respectively[23-25]. These findings suggest that paramyxoviral M proteins may execute roles beyond viral assembly at the plasma membrane.

RNA viruses have adeptly evolved to exploit the machinery of host cells, a necessity stemming from their relatively limited genome capacity compared to DNA viruses. By co-opting the host cell machinery, they can potentiate their own replication. RNA viruses employ diverse strategies to inhibit host mRNA expression while selectively enhancing translation of viral mRNAs[26-28]. This targeted modulation of host and viral mRNA translation is believed to suppress antiviral responses, thereby facilitating viral replication within host cells. For instance, the SARS-CoV-2 Nsp1 binds to the ribosomal mRNA channel, inhibiting translation and inducing the degradation of translated cellular mRNAs, leading to a global reduction in protein translation[29-31]. Similarly, the Influenza A virus induces host translation shutoff by reducing the amount of host mRNA in cells[32-34] and cap-snatching of cellular pre-mRNAs to prioritize viral transcripts[35,36]. Enteroviruses, such as poliovirus and coxsackievirus B3, use

76   2A proteinases to cleave eIF4G1 and PABP, resulting in rapid host translation shutoff and

77   directing ribosomes to IRES-contained viral mRNAs[37-39]. Additionally, the matrix protein of the

78   vesicular stomatitis virus (VSV) causes a global inhibition of host gene expression by

79   interacting with the TFIIH transcription factor and forming a complex with Rae1 and Nup98

80   to disrupt mRNA export amongst other mechanisms yet to be defined[40-42]. In PMVs,

81   parainfluenza virus 5 (PIV5) manipulates host cell translation through its P and V proteins,

82   and the nuclear localization of matrix from NDV appears crucial for suppressing host cell

83   transcription[43,44]. However, the specific mechanisms by which PMVs modulate host cellular

84   translation for their own benefit remain obscure and have not been systematically examined.

85

86   Our previous studies have demonstrated the ubiquitin-regulated nuclear-cytoplasmic

87   trafficking behavior of paramyxovirus matrix proteins, indicating a non-structural function

88   within the nucleus that remains to be determined[14,16]. In this study, we explore an additional

89   non-structural function of the viral matrix within the cytoplasm. We reveal that PMV matrix

90   proteins inhibit host cell nascent peptide synthesis during infection by interacting with the

91   core exon-junction complex (cEJC). This interaction enhances viral mRNA translation while

92   suppressing host mRNA translation by promoting the association of viral mRNAs with

93   ribosomes, thereby increasing their translation efficiency. The matrix-cEJC interaction occurs

94   primarily in the cytoplasm, where matrix-induced re-localization of cEJC is observed during

95   infection. Depletion of cEJC significantly enhances PMV replication, underscoring the critical

96   role of this interaction. These findings suggest a model whereby PMV matrix redirects

97   ribosomes to translate viral mRNAs, enhancing viral replication and providing insights into

98   how HPIV3 manipulates host translation machinery.

4

99 **RESULTS**

100 **HPIV3 matrix inhibits host protein synthesis during viral infection.**

101 To interrogate how paramyxovirus infection affects host protein synthesis, we utilized

102 puromycylation to capture a snapshot of protein synthesis. The sensitivity of puromycylation

103 in HEK-293Ts was first determined by treating cells with either mock or cycloheximide (CHX)

104 to block translation, followed by a puromycin pulse to label newly synthesized proteins. CHX-

105 treated cells showed >50% reduction in puromycin-incorporated proteins (Figure 1A, lane 3),

106 demonstrating that puromycylation can quantitatively detect inhibited protein synthesis as

107 expected[45]. We then evaluated the effect of HPIV3 infection on host protein synthesis. A 14%

108 reduction in protein synthesis was noted at 24 hours post-infection (hpi) that became more

109 pronounced at 48 hpi, approaching 35% decrease in synthesis compared to control cells

110 (Figure 1B). An even more dramatic inhibitory effect on protein synthesis was evident in cells

111 infected with Cedar virus (CedV) (Figure 1C, 82% decrease at 24 hpi), a non-pathogenic

112 henipavirus within the *Paramyxoviridae* family. These results suggest that paramyxoviruses,

113 such as HPIV3 and CedV employ strategies to disrupt host protein synthesis. Next, we sought

114 to identify the viral determinants contributing to this disruption by examining cells expressing

115 each FLAG-fused HPIV3 viral protein. Expression of the HPIV3 matrix led to a nearly 40%

116 reduction in puromycylated proteins (Figure 1D, lane 4), whereas other viral proteins did not

117 exhibit a similar effect. Notably, cells expressing nucleocapsid and phosphoprotein showed

118 increased puromycylation, potentially reflecting their high expression levels. These findings

119 suggest that the HPIV3 matrix plays a crucial role in inhibiting host protein synthesis.

120

121 To further elucidate the temporal effects of the HPIV3 matrix on host protein synthesis, cells

122 were examined at various post-transfection intervals and those expressing HPIV3 matrix

123 trafficking mutants. Host protein synthesis was notably inhibited by the HPIV3 matrix at 24

124 hpi, with almost 60% inhibition observed at 48 hpi (Figure 1E, lanes 2 and 4). To determine

125 whether the inhibitory effects of the HPIV3 matrix protein were due to its cytoplasmic or

126 nuclear pools, we generated cytoplasmic- and nuclear-resident mutants based on the well-

127 defined nuclear localization signals (NLS) and nuclear export signals (NES) demonstrated for

128 the NiV matrix [16]. The HPIV3-M mutants exhibited similar distribution patterns to those of

129 NiV-M as assessed by the cytoplasmic-to-nuclear (C/N) ratio of HPIV3-M intensities in

130 transfected HeLa cells (Figure S1). Cytoplasmic-resident mutants (Bp12) from HPIV3 and NiV

131 exhibited a stronger inhibitory effect compared to their wild-type (WT) counterparts (Figure

132 1F, lanes 3 and 6). Conversely, nuclear-resident mutants (LL) showed a reduced inhibitory

5

133   impact relative to the WT (Figure 1F, lanes 4 and 7). These findings highlight the importance

134   of matrix localization in modulating host protein synthesis.

135

136   Finally, to determine if matrix solely modulates host protein synthesis during HPIV3 infection,

137   we infected cells with either HPIV3 (WT) or its matrix-deleted mutant (HPIV3ΔM) (see

138   methods) and assessed global protein synthesis as before. Unlike WT, HPIV3ΔM failed to

139   inhibit host protein synthesis at 24- and 48 hours post-infection (Figure 1G, lanes 3 and 6).

140   This finding emphasizes the pivotal role of the matrix in regulating host protein synthesis

141   during HPIV3 infection. Taken together, these results clearly demonstrate that the HPVI3

142   matrix inhibited host protein synthesis during infection.

143

144   **Viral matrix enhances viral but suppresses host protein expression at the**

145   **translational level.**

146   Given that the viral matrix can inhibit host protein expression, we aimed to investigate the

147   specific stages of viral and host protein expression targeted by the viral matrix protein,

148   determining whether its effects occur at the level of mRNA transcription or translation. To

149   address this, we engineered a stable cell line expressing a rNiV-NPL replicon (Haas G et al,

150   manuscript in preparation), which encodes essential genes for viral transcription and genome

151   replication in the cell; N, P, L, and a luciferase (Luc) reporter between N and P genes. This

152   replicon allows the production of single-cycle infectious virus-like particles (VLPs) by co-

153   transfecting the NiV matrix, fusion, and receptor-binding proteins (M, F, and RBP). These

154   rNiV-VLPs can infect cells but not produce new virus particles, ensuring that all readouts

155   originate from the initial inoculation. Importantly, the effects of matrix on viral gene and

156   protein expression can be studied by exogenous addition of matrix. Cells expressing increased

157   amounts of NiV-M, followed by infection with rNiV-NPL-VLP, exhibited enhanced Luc activity

158   (Figure 2A, lanes 2-3 compared to Lane 1). Similarly, the HPIV3 matrix, from a different

159   paramyxovirus genus, also enhanced Luc activity (Figure 2A, lanes 4-5 compared to Lane 1).

160   Moreover, increased amounts of matrix protein inhibited host protein synthesis (Figure 2A,

161   lower panel). Analysis of viral RNA expression levels for N, P, and L genes, as well as the viral

162   genome and anti-genome, revealed no significant changes regardless of the presence of

163   matrix proteins. This indicates that the observed enhancement was specific to the translation

164   process and not due to increased mRNA transcription.

165

166   To further assess the generalizability PMV matrix inhibiting host protein expression, cells were

167   co-transfected with matrix proteins from multiple PMV genera and an intron-containing Luc

168 reporter (Luc-I) as previously described[46]. The results showed a universal suppression of Luc

169 activity, with the GhV matrix showing a greatest reduction at 90% (Figure 2G, lane 5), while

170 the MeV matrix resulted in a lesser, but still significant, 50% reduction (Figure 2G, lane 7).

171 To determine if this decrease in Luc activity is effectuated at the transcriptional or translational

172 level, we first generated a standard dose-response curve showing a dose-dependent increase

173 in Luc transcripts and (protein) activity levels in cells transfected with increasing amounts of

174 Luc-I (Figure 2H). Using these standard curves, we analyzed the relative levels of Luc

175 transcripts and activity in cells expressing either empty vector (EV), GhV, or MeV matrix, and

176 observed no significant changes between Luc transcript levels and activity in the EV and MeV

177 conditions. However, cells expressing the GhV matrix showed a marked suppression in Luc

178 activity despite only a marginal reduction in Luc transcripts (Figure 2I).

179 These results collectively suggest that the viral matrix proteins enhance viral protein

180 translation without affecting mRNA transcription and suppress host protein translation at the

181 mRNA translational level.

182

183 **HPIV3 matrix promotes ribosome association of viral mRNAs during infection.**

184 To assess the impact of HPIV3 infection on host mRNA translation, we performed polysome

185 profiling analysis using HEK-293Ts that were either mock-infected, infected with HPIV3, or

186 transfected with the HPIV3 matrix protein. The polysome profile (Figure S2A) from mock-

187 infected cells (black line) displayed distinct peaks corresponding to the 40S and 60S ribosomal

188 subunits, the 80S monosome, and polysomes, which serve as a baseline. Upon HPIV3

189 infection (blue line), there was a noticeable accumulation of 80S monosomes, particularly in

190 fractions 6-7, a phenomenon also observed in other viruses such as VSV[47]. This accumulation

191 was further confirmed by densitometry of western blotted proteins across all fractions, which

192 showed increased intensities of small (S6) and large (S7a) ribosomal proteins in their

193 respective cognate fractions (Figure S2B-D). In cells transfected with the HPIV3 matrix protein

194 alone, there was an even more pronounced peak of 80S monosomes, accompanied by a

195 decrease in polysome fractions. Immunoblotting for cEJC components (Figure S2B), including

196 eIF4AIII, Y14, and MAGOH, showed consistent distribution across the ribosomal fractions,

197 aligning with the previous study[48].

198

199 To further characterize the impact of the matrix protein on viral and host translational profiles

200 during infection, we generate a recombinant HPIV3ΔM with the matrix gene substituted by

201 an mCherry reporter, so we could perform polysome transcriptional profiling using isogenic

202 HPIV3 infected cells that differ only in virus expressed M protein. Polysome profile analysis of

203 cells infected with HPIV3 revealed an increase in the 80S monosome pool 48 hours post-
204 infection (Figures 3A, blue line), relative to mock-infected cells (Figure 3A, black line). This
205 confirms the polysome profile presented in Figure S2. However, this increase was abrogated
206 in cells infected with HPIV3ΔM (Figures 3A, red line), indicating a potential role of the matrix
207 protein in monosome accumulation. Next, we isolated free, monosome- and polysome-
208 associated mRNAs and quantified their relative abundance through mRNA sequencing (mRNA-
209 Seq). Sequence alignments to both viral and host genomes revealed that around 10% of the
210 total reads across all fractions were viral, a pattern consistent in cells infected with HPIV3
211 (Figure 3B), consistent with observations reported for parainfluenza virus 5 (PIV5), another
212 paramyxovirus[49]. However, the amount of viral reads reduced to 4% of total reads in cells
213 infected with the HPIV3ΔM virus, suggesting a decrease in viral mRNA abundance (Figure 3C).
214 Examination of the distribution of viral transcripts across all seven genes showed that
215 HPIV3ΔM did not alter the transcriptional gradient characteristic of paramyxoviruses (Figure
216 3 D and E). To measure the proportion of viral mRNAs associated with ribosomes, we
217 calculated the ratio of each viral mRNA's proportion in the ribosome-associated fraction
218 (fractions 7-16) to its proportion in the free fraction (fractions 3-4), which we term "ribosome
219 association efficiency." Comparative analysis of the ribosome association efficiency between
220 HPIV3 and HPIV3ΔM-infected cells revealed a higher ribosome association ratio for viral
221 transcripts in HPIV3 (Figure 3F and Data S1).

222 Taken together, these findings suggest that the matrix potentially enhances viral mRNA
223 translation efficiency by promoting the association of viral transcripts with ribosomes, thereby
224 facilitating more efficient viral translation during infection.

225

226 **HPIV3 matrix exhibits a minimal impact on the abundance of individual cellular**
227 **mRNAs in the monosome and polysome fractions.**

228 To determine how the HPIV3 matrix affects the distribution of mRNAs between monosome
229 and polysome fractions, we plotted the transcripts per million (TPM) for each cellular mRNA
230 mapped to the human genome in both fractions. In the monosome fraction, which represents
231 transcripts at the initial stage of translation, the expression abundance of cellular transcripts
232 was similar in both HPIV3 and HPIV3ΔM infections (Figure 4A and Data S2). This similarity
233 indicates that the viral matrix did not significantly alter *relative* cellular gene expression, as
234 shown by the comparable relative transcript ratios between HPIV3 and HPIV3ΔM infections
235 (Figure 4B). In the polysome fraction, representing actively translating transcripts, the
236 expression abundance of cellular transcripts also showed no significant differences between
237 HPIV3 and HPIV3ΔM infections (Figure 4C). The matrix protein altered the abundance of

238 cellular transcripts within a narrow range, with few genes exhibiting more than a 2-fold change
239 in the relative transcript ratio (Figure 4D). Overall, these results suggest that during HPIV3
240 infection, the presence of the viral matrix protein does not cause significant changes in the
241 translation of cellular transcripts. The distribution of mRNAs between monosome and
242 polysome fractions remains largely consistent, indicating that the matrix protein has a
243 minimal impact on overall cellular gene expression at the translational level.

244

245 **Paramyxoviral-matrix proteins interact with the core components of the exon**
246 **junction complex.**
247 We have found that the matrix disrupts host protein expression at the translation level (Figure
248 2). To address how the matrix protein disrupts host translation, we sought to identify its
249 potential cellular targets. An inducible 293Ts expressing FLAG-fused NiV-M was generated,
250 enabling the efficient co-purification of NiV-M interacting proteins. The composition of these
251 M-interacting proteins was then characterized using proteomic mass spectrometry, following
252 methods delineated in the previous study[14]. Using the CORUM protein complex database, we
253 discovered a significant enrichment of proteins associated with the exon junction complex
254 (EJC) within the NiV-M interactome (Figure 5A, with a -log10 (adjusted p-value) > 4). The
255 EJC serves as a multifaceted regulator of mRNA biogenesis, including core proteins such as
256 eIF4AIII, Y14, and MAGOH, which were found to interact with NiV-M. To determine whether
257 matrix proteins from various paramyxoviruses interact with the EJC components, we
258 performed co-immunoprecipitation (co-IP) and immunoblot analysis.
259 Cells expressing FLAG-fused matrix from 8 different paramyxoviruses were subjected to
260 immunoprecipitation using Anti-FLAG M2 affinity beads. The results revealed that the core
261 components of EJC (cEJC), the eIF4AIII, Y14, and MAGOH were all present in matrix
262 precipitants (Figure 5B, lane 2-9), but not in the FLAG precipitant (vector control, lane 1). To
263 ensure that the interaction between matrix and cEJC is RNA-independent, we conducted a
264 similar experiment with the addition of RNase A to each reaction. The amount of cEJC in
265 matrix immunoprecipitants was unchanged, or in some cases, even increased (Figure 5B,
266 RNase A +), suggesting the RNA-independent association between the paramyxoviral matrix
267 proteins and the cEJC components.

268

269 To ensure that matrix-cEJC interactions were not an artifact of matrix overexpression during
270 transient transfections, we sought to validate the interaction between the matrix and the cEJC
271 during infection. We infected 293T cells with either wild-type HPIV3 (WT) or a previously
272 characterized isogenic counterpart expressing an HA-tagged matrix protein (HPIV3_HA-M)[50]

273 and conducted HA-IP at 48 hpi. Notably, cEJC components were detected exclusively in HA-
274 coprecipitates from cells infected with the HPIV3_HA-M, but not in those from WT-infected
275 cells (Figure 5C, lanes 1 and 2), thereby validating the specific interaction between the matrix
276 and cEJC in the context of HPIV3 infection. Having verified the interaction between matrix
277 and cEJC, we next wanted to assess where this matrix-cEJC interaction occurred as both
278 matrix and cEJC components are known to undergo nuclear-cytoplasmic trafficking. 293Ts
279 expressing FLAG-tagged matrix from HPIV3, NiV, and CedV were subjected to cytoplasmic-
280 nuclear fractionation. FLAG-IP was then employed to determine the interaction dynamics of
281 the matrix proteins and cEJC within these fractions. Analysis of the input (Figure 5D, lanes 5
282 to 12) revealed that the cEJC components were more abundantly present in the cytoplasm
283 compared to the nucleus. Additionally, FLAG-tagged matrix proteins from HPIV3, NiV, and
284 CedV showed a relatively even distribution between the cytoplasmic and nuclear fractions.
285 Following the IP, results revealed that the band intensities for cEJC co-IPed with the matrix
286 were markedly stronger in the cytoplasmic fractions compared to the nuclear (Figure 5D,
287 lanes 2 to 4). Quantification of these bands yielded cytoplasm-to-nucleus intensity ratios
288 consistently greater than 1 (Figure 5D, C/N ratio), suggesting a preferential interaction within
289 the cytoplasm. These results collectively indicate that the matrix-cEJC interaction
290 predominantly occurs within the cytoplasm, highlighting a potential mechanism by which the
291 matrix protein disrupts host translation.

292

293 **HPIV3 infection perturbs the subcellular distributions of core EJC components.**
294 To potentiate its own replication, viruses have evolved strategies to co-opt or antagonize
295 functions of cellular proteins, including altering their expression levels and localization.
296 Although we did not detect a significant change in the abundance of cEJC during HPIV3
297 infection (Figure 6A), we suspected that HPIV3 infection might alter the localization of these
298 proteins as described in previous studies with flaviviruses[51-53]. We performed cytoplasmic-
299 nuclear fractionation in HPIV3-infected cells and monitored the relative abundance of cEJC in
300 the cytoplasmic and nuclear fractions (Figure 6B). We observed an increased abundance of
301 eIF4AIII, Y14, and MAOGH in the cytoplasmic fraction, with a concomitant decrease in the
302 nucleus fraction during infection, while the total amount of cEJC remained unchanged in the
303 infected whole cell lysates. Densitometric quantification of the cognate band intensities
304 showed that the cytoplasmic: nuclear ratios of eIF4AIII, Y14, and MAOGH increased 3-5 fold
305 at 24 hpi. To gain further insights, we visualized the localization of the HPIV3 matrix and cEJC
306 components in HPIV3-infected cells via confocal microscopy. We first address whether the
307 HPIV3 matrix exhibits a similar trafficking behavior to the NiV matrix, as previously

308   reported[14,16]. The cytoplasmic matrix translocated into the nucleus at 12-16 hpi and then
309   returned to the cytoplasm by 24 hpi (Figure S3A). This was further confirmed by the increased
310   cytoplasmic-to-nuclear (C/N) ratio of HPIV3-M intensities (Figure S3B). At 24 hpi, the HPIV3
311   matrix was observed at the plasma membrane of infected cells, consistent with its role in the
312   budding process of mature virions (Figure 6C-E). Compared to the mock, HPIV3 infection
313   appeared to disrupt the distribution of cEJC components, leading to their accumulation in the
314   cytoplasm, consistent with our previous fractionation results. More importantly, we observed
315   partial, rather than complete, colocalization of matrix and cEJC components in cytoplasmic
316   puncta (Figure 6C-E, orthogonal projections), suggesting that viral matrix may modulate the
317   cytoplasmic function of the EJC, such as mRNA translation. To further confirm that the HPIV3
318   matrix is responsible for the accumulation of cEJC in the cytoplasm, we monitored the
319   distribution of the eIF4AIII in cells infected with HPIV3ΔM. Compared to the HPIV3, the ΔM
320   virus lost the ability to redistribute the eIF4AIII (Figure 6F), as indicated by the low C/N ratio
321   of eIF4AIII intensities.
322   Taken together, these findings demonstrate that the HPIV3 matrix induces the redistribution
323   of cEJC components to the cytoplasm, leading to their partial cytoplasmic colocalization with
324   the matrix. cEJC typically docks on nascent mRNAs after splicing, serving as a platform for
325   factors involved in mRNA export and enhancing mRNA translation efficiency. These
326   components are usually recycled back into the nucleus to continue their role in mRNA
327   biogenesis; this co-localization in the cytoplasm might restrict the cellular functions of the
328   cEJC, potentially impacting host mRNA translation during infection.
329

330   **Enhanced viral gene translation through eIF4AIII knockdown and matrix**
331   **expression.**
332   To ascertain the role of cEJC components, specifically eIF4AIII, in the stages of viral
333   replication, we utilized the rNiV-NPL replicon system described in Figure 2. The knockdown of
334   eIF4AIII was employed to simulate the restriction of cellular functions by the viral matrix,
335   allowing us to closely examine the impact of eIF4AIII on viral mRNA transcription and
336   translation. Cells were co-transfected with either negative control siRNA (siNC) or siRNA pool
337   targeting eIF4AIII (sieIF4AIII) along with an empty vector (EV) or plasmids expressing
338   increased amounts of NiV-M or HPIV3-M for 24 hrs. The cells were then infected with rNiV-
339   NPL-VLP, and Luc activity was measured to indicate the level of viral gene translation.
340   Compared to siNC, the knockdown of eIF4AIII enhanced Luc activity in the rNiV-NPL-VLP
341   infected cells (Figure 7A upper panel, lane 2 vs. lane 1); knockdown of eIF4AIII also slightly
342   inhibited host protein synthesis as indicated by the western blot (lower panel, Lane 2 vs. Lane

343   1). In the eIF4AIII knockdown background, the addition of NiV or HPIV3 matrix further
344   enhanced Luc activity in a dose-dependent manner (Lanes 3-6 vs. Lanes 1 and 2). The RNA
345   levels of the viral genes and genomes showed minor changes (less than 2-fold) in cells
346   expressing EV or matrix proteins in the eIF4AIII knockdown background compared to the cell
347   expressing EV in the NC knockdown background (Figure 7B-7F), which was not as pronounced
348   as the changes observed in Luc activity. These findings suggest that the partial knockdown of
349   eIF4AIII leads to a slight reduction in host protein synthesis but enhances viral gene
350   translation, suggesting a redistribution of translational resources to viral mRNAs. Furthermore,
351   the expression of the viral matrix in cells with partial eIF4AIII knockdown further restricts the
352   function of the remaining eIF4AIII, enhancing viral gene translation. Thus, we propose that
353   the viral matrix enhances viral gene translation by restricting the cellular function of eIF4AIII.
354
355

356   **Core EJC depletion can enhance paramyxovirus replication**
357   Building on our findings that partial knockdown of eIF4AIII enhances viral gene translation
358   when viral matrix proteins are expressed, we further explored the functional role of core EJC
359   components in authentic paramyxovirus replication. To do this, we utilized siRNA-mediated
360   knockdown (KD) targeting cEJC components: eIF4AIII, Y14, MAGOH, as well as a non-
361   targeting siRNA control. These siRNAs were transfected in 293Ts for 48 hrs prior to infection
362   with a panel of GFP-reporter paramyxoviruses encompassing the 3 major subfamilies of
363   paramyxoviruses, including Human Parainfluenza Virus 3 (HPIV3) and Cedar virus (CedV)
364   (*Orthoparamyxovirinae*), Mumps virus (MuV) (*Rubulavirinae*), or Newcastle Disease Virus
365   (NDV) (*Avulavirinae*). The KD of cEJC components led to an increase by up to 8-fold in the
366   number of infected (GFP-positive) cells across all tested paramyxoviruses (Figure S4). The
367   viral titers were also assessed at 24, 48, or 72 hours of post-infection and demonstrated a
368   more marked increase in cells with cEJC KD, with varying magnitudes of enhancement.
369   Notably, MAGOH KD in HPIV3-infected cells led to a two-log increase in viral titer 48 hpi
370   compared to the non-targeting control (Figure 8A); a comparable trend was also observed in
371   CedV-infected cells with MAGOH depletion (Figure 8B). Conversely, cells with Y14 depletion
372   showed the most pronounced titer increase for MuV and NDV at 72 hours post-infection
373   (Figure 8C-D), suggesting that the observed effects might be influenced by the unique
374   replication dynamics inherent to each virus. To determine if the effect of cEJC KD was specific
375   to paramyxoviruses, we further examined the effects of cEJC on the replication of other RNA
376   viruses such as influenza A, enterovirus D68, and SARS-CoV-2. cEJC depletion did not
377   universally augment the replication of these viruses (Figure 8E-G). In the case of influenza A

378   virus replication, eIF4AIII KD slightly decreased viral titers, consistent with previous reports[54]

379   implicating eIF4AIII as a positive regulator of IAV replication.

380   Collectively, our results indicate that core EJC depletion can significantly and specifically

381   enhance the replication of paramyxoviruses, with the extent of enhancement varying among

382   different viruses.

383

384 **DISCUSSION**

385   In this study, we uncovered a novel mechanism by which the HPIV3 matrix manipulates host

386   cell machinery to promote viral translation. Our findings demonstrate that the HPIV3 matrix

387   significantly inhibits host protein synthesis while enhancing viral protein translation, primarily

388   through increased ribosome association with viral mRNAs. Remarkably, we identified a

389   previously unrecognized interaction between the paramyxoviral matrix and core components

390   of the exon junction complex (EJC), predominantly occurring in the cytoplasm. This interaction

391   leads to altered subcellular distribution of EJC components during infection. Functional studies

392   revealed that depletion of EJC components enhances viral gene translation and replication

393   specifically for paramyxoviruses. These results illuminate a strategy employed by

394   paramyxoviruses to subvert host cellular processes, offering new perspectives on virus-host

395   interactions.

396   The paramyxoviral matrix is known as a structural component localized in the cytoplasm.

397   Several studies, however, have uncovered the nuclear sojourn of the matrix during MeV and

398   NDV infections and transfections, suggesting a role beyond structural functions. One of these

399   nuclear functions is the suppression of host mRNA transcription, which significantly impacts

400   the host's antiviral response. Despite these findings, the effect of the paramyxoviral matrix

401   on host translation remains unexplored. Using puromycylation to monitor newly synthesized

402   proteins, we have discovered that paramyxovirus infection results in a partial shutdown of

403   host protein synthesis, a phenomenon not previously reported (Figure 1B-C). Our findings

404   indicate that this inhibitory effect on host protein translation is solely attributed to the viral

405   matrix (Figure 1D and 1G). Further investigation into the stages of protein synthesis targeted

406   by the matrix revealed that the disruption occurs at the mRNA translation level (Figure 2).

407   This discovery underscores the significance of the matrix's localization in hindering host

408   translation. The matrix protein's ability to inhibit host protein synthesis at this specific stage

409   highlights its strategic role in manipulating the host's translational machinery to favor viral

410   replication.

411   To characterize the cellular localization of the HPIV3 matrix, sequence alignment is

412   performed in HPIV-M with NiV-M whose NLS and NES sequences are well defined in the

413   previous studies. Putative NLS (Mbp1/2) and NES (L106A L107A) mutants were introduced

414   into GFP-fused HPIV3-M to visualize their localization in expressing cells. Indeed, Cells

415   expressing WT or mutants all resemble similar distributions as we previously observed in the

416   NiV-M (Figure S1)[14,16]. Furthermore, the localization of HPIV3 during infection (Figure S3)

417   reveals that HPIV3-M has the same trafficking behavior as previously demonstrated in NiV-

418   infected HeLa cells[16]. Similar to the NiV-M, HPIV3-M translocases into the nuclear at early

419   time points (12 to 16 hrs) and distributes into the cytoplasm and the plasma membrane at

420   later time points (20 to 24 hrs). The distribution of HPIV3-M in the cytoplasm might explain

421   several observations in this study:

422   1. The subcellular localization is critical for the matrix to modulate host translation since the

423   NES mutant of both HPIV-M and NiV-M shows reduced levels of the inhibitory effect by matrix

424   (Figure 1F).

425   2. Paramyxoviral matrixes suppress host protein synthesis at least, at the mRNA translation

426   level – since mRNA translation also occurs in the cytoplasm (Figure 2A, G, and H).

427   3. The matrix-cEJC interaction and co-localization are mainly detected in the cytoplasm

428   (Figure 5D and 6C-6E). These observations emphasize the importance of the cytoplasmic-

429   resident matrix for modulating host translation. The expression of wild-type or mutant HPIV3-

430   M alone also shows the cytoplasmic retention of endogenous eIF4AIII at similar levels (Figure

431   S5). However, the pattern of eIF4AIII cytoplasmic retention appears slightly different

432   compared to HPIV3 infection (Figure 6F), as more cytoplasmic puncta are observed during

433   infection. This difference may be due to the matrix co-opting with other viral factors to form

434   liquid-liquid phase separation puncta.

435   EJC serves as a multifaceted modulator of mRNA biogenesis, it travels with mRNA across

436   different cellular landscapes from pre-mRNA splicing to downstream, posttranscriptional

437   processes such as mRNA export, mRNA localization, translation, and nonsense-mediated

438   mRNA decay (NMD)[55-57]. While NMD is known to impact the infection dynamics of

439   flaviviruses[51-53], and viruses have evolved various mechanisms to evade or hijack NMD[58,59], it

440   remains unclear whether HPIV3 infection exerts any interference on NMD activity. To

441   interrogate the effect of HPIV3 infection on NMD activity, we assessed the levels of

442   endogenous NMD targets as delineated in a previous study[53], which includes SC35,

443   GABARAPL1, ASNS, and CARS. We found that the expression of these NMD targets increases

444   at 48 hours post-infection, suggesting that NMD is impeded by HPIV3 infection (Figure S6).

445   To further decipher whether this suppression is a consequence of the matrix-cEJC interaction,

446   we transfected cells with vectors expressing either GFP or HPIV3-M to monitor the effects of

447   the matrix on NMD activity. To our surprise, the overexpression of HPIV3-M did not disrupt

448   NMD activity, suggesting that the observed inhibitory effects on NMD may be attributed to

449   other viral factors, not the matrix (Figure S7).

450   The differential impact of cEJC depletion on the replication of paramyxoviruses versus

451   Influenza, SARS-CoV-2, and EVD68 offers intriguing insights into the unique strategies

452   employed by these viruses to hijack host translation machinery. Understanding these

453   mechanisms explains why cEJC depletion benefits paramyxovirus replication but not the other

454   viruses. SARS-CoV-2 NSP1 inserts into the mRNA entry channel on the 40S ribosomal subunit,

455   blocking host mRNA loading for translation initiation. It also interacts with the mRNA export

456   receptor NXF1-NXT1 and NPC proteins (Nup358, Nup214, Nup153, Nup62), preventing proper

457   mRNA export and fostering viral mRNA translation in the presence of the SL1 5'UTR

458   hairpin[29,60,61]. Influenza virus takes over host translation by cap-snatching cellular pre-mRNAs,

459   inhibiting pre-mRNA polyadenylation, and preferentially translating viral mRNAs through

460   sequences in the viral mRNA 5'-UTR[33-36,62,63]. It also retains cellular mRNAs in the nucleus by

461   inhibiting pre-mRNA splicing and blocking mRNA nucleocytoplasmic transport[64-66]. Enterovirus

462   hijacks host translation by using viral proteinase 2A to cleave eIF4E, leading to a global

463   shutdown of Cap-dependent translation, and redirecting ribosomes to viral mRNAs via IRES

464   elements[38,39]. The aggressive global shutoff mechanisms of SARS-CoV-2, Influenza, and

465   EVD68 might overshadow any potential benefits from cEJC depletion, rendering any changes

466   unobservable. In contrast, the paramyxoviral matrix might not completely antagonize cEJC's

467   cellular function, as evidenced by partial host translation suppression and colocalization of

468   matrix and cEJC (Figure 1 and Figure 6C-E). During paramyxovirus infection, both cellular

469   and viral mRNA are capped and polyadenylated, meaning the virus needs to outcompete for

470   translation resources. The key difference is that host mRNA is docked with EJCs at exon-exon

471   junctions during the pioneer round of translation, while viral RNA is not. Consequently, the

472   depletion of cEJC might inhibit the translation of EJC-bound cellular mRNA, thereby redirecting

473   translational resources to viral mRNA. Moreover, the depletion of cEJC mimics the matrix

474   interaction within the cytoplasm, sequestering EJC-bound cellular mRNA away from the

475   translation apparatus. Additionally, the paramyxoviral matrix might selectively enhance viral

476   mRNA translation, further facilitating the virus's ability to hijack the host's translation

477   machinery. Future work uncovering the means for matrix specificity on viral mRNA may

478   unearth novel strategies for selective translational control during viral infection.

479

480

491

492 **AUTHORS CONTRIBUTIONS**

493 C-T.H. P.T. and B.L. designed research

494 C-T.H., G.D.H., R.E.W., H.P.C, S.K., A.P and J.A.W. performed research

495 G.D.H. contributed new reagents

496 C-T.H., C.S.S., and B.L. analyzed data

497 C-T.H. and B.L. wrote the paper.

498

499 **DECLARATION OF INTERESTS**

500 The authors declare no competing interests.

501

502 **FIGURE TITLES AND LEGENDS**

503 **Figure 1. Puromycylation of newly synthesized protein in paramyxovirus-infected**

504 **or viral proteins transfected HEK-293T cells.**

505 (A) HEK-293Ts were treated with either mock or cycloheximide (CHX) at 200 µg/ml for 5

506 hours, followed by a 20-minute treatment with either mock or puromycin at 10 µg/ml. After

507 the puromycin pulse, cells were washed with PBS and re-fed with complete media. Lysates

508 were analyzed by immunoblotting, and newly synthesized (puromycylated) proteins were

509 probed using an anti-puromycin antibody. (B-C) HEK-293Ts were inoculated with mock,

510 HPIV3, or Cedar virus and puromycin pulsed at indicated time points. Lysates were

511 immunoblotted to probe puromycylated proteins. The expression of HPIV3 nucleocapsid (N)

512 and EGFP served as controls for HPIV3 and Cedar infections, respectively. (D) Flag-fused viral

513 proteins from individual HPIV3 genes or an empty vector (EV) were expressed in HEK-293T

514 cells for 48 hours, followed by puromycylation and immunoblot analysis to detect

515 puromycylated proteins. Expression of viral proteins was detected with an anti-FLAG antibody,

17

516   with molecular weights indicated by black arrows. F0: F precursor. F1: cleaved F. (E-F) HEK-
517   293T cells were expressed designated FLAG-fused matrix (M) proteins from HPIV3 or NiV,
518   including wild-type (WT) and mutants (Bp12: NLS mutant, LL: NES mutant), along with EV
519   control for 24 or 48 hrs. Following puromycylation, immunoblotting was conducted to
520   determine the puromycylated protein and flag-fused matrix. (G) HPIV3 or HPIV3ΔM virus-
521   infected HEK-293Ts were analyzed by immunoblotting after puromycylation at 24- and 48-
522   hrs post-infection to detect puromycylated protein and HPIV3 viral proteins. HPIVP3-N and
523   HPIV3-M served as infection control. The numbers below each column indicate the relative
524   protein abundance measured by densitometry and normalized as described in the Materials
525   and Methods.

526

527   **Figure 2. Effects of paramyxoviral-matrix on Nipah-NPL replicon and the expression**
528   **of cellular splicing-dependent luciferase.**

529   (A) HEK-293Ts were transfected with either NiV or HPIV3 matrix for 24 h. Following
530   transfection, cells were inoculated with NiV-NPL replicon virus-like particles (VPL) and
531   incubated for an additional 48 hours. Relative luciferase activity was measured using the
532   Nano-Glo HiBiT system (upper panel). Puromycin-pulsed cells were analyzed by
533   immunoblotting to assess protein expression levels (lower panel). (B-F) Total RNA was
534   extracted from cells treated as in (A) and subjected to RT-qPCR. Relative viral transcript
535   quantity (RQ) was normalized to GAPDH expression. (G) Luciferase activity (RLU) in HEK-
536   293Ts co-transfected with paramyxoviral matrix protein and intron-containing luciferase
537   reporters (Luc-I) for 24 h. RLU was detected using the ONE-Glo system. Expression of FLAG-
538   fused matrixes was analyzed by immunoblotting. Relative luciferase expressions were
539   normalized to EV. (H) A standard curve showing RLUs versus transcripts in HEK-293Ts
540   transfected with varying amounts of Luc-I reporter (250 ng to 0.98 ng, 4-fold serial dilution).
541   RLUs were measured using the ONE-Glo system, and transcript levels relative to 18S rRNA
542   were determined by RT-qPCR. Relative levels were normalized to cells transfected with the
543   maximum amount of Luc-I reporter. (I) Relative levels of RLU and transcripts in HEK-293Ts
544   co-transfected with designated viral matrix and Luc-I reporter. RLUs and transcripts were
545   measured as described in (H). With relative levels normalized to EV. Symbols are data points
546   from biological triplicates. Bar represents the mean ± SD. Statistical significance was
547   determined by one-way ANOVA with Dunnett multiple comparison test. ** P <0.01; **** P
548   <0.0001; ns, not significant.

549

Figure 3. Polysome profile and viral transcript distribution in HPIV3 and HPIV3ΔM infected cells.

(A) Polysome profiles of mock-infected (black), HPIV3 infected (blue), or HPIV3ΔM infected (red) HEK-293Ts at 48 hrs post-infection (hpi). HEK-293Ts were infected with HPIV3 or HPIV3ΔM at MOI of 3. Cytoplasmic extracts were prepared at 48 hpi and subjected to sedimentation through a 10-50% sucrose gradient. Absorbance at 254 nm was continuously monitored, and 0.6 ml fractions were collected. Distribution of fragments mapping to (B) human and HPIV3 or (C) human and HPIV3ΔM genome across the sucrose gradient fractions 7 to 16 at 48 hpi. (D-E) Distribution of viral transcript among the seven viral genes of either HPIV3 or HPIV3ΔM infected HEK-293Ts at 48 hpi. The percentage of mapped viral transcripts was quantified using the transcripts per kilobase Million (TPM) metric to normalize for gene length and library size. (F) Comparative analysis of ribosome association efficiency of viral transcripts in HPIV3 and HPIV3ΔM infected cells. Statistical significance was analyzed by Wilcoxon test. * P <0.05.

Figure 4. Effects of HPIV3 matrix on the relative abundance of individual cellular mRNAs between monosome and polysome.

(A) Scatter plots of transcripts per kilobase Million (TPM) for cellular mRNA transcripts in monosome fraction at 48 hpi. The x-axis graphed unique cellular mRNAs from mock-infected cells, and the y-axis depicted the corresponding TPM values for each mRNA in either mock-infected (gray circles), HPIV3-infected (blue circles) or HPIV3ΔM infected cells (red triangles). (B) Density plots of the log2 fold change in TPM for cellular mRNAs between virus-infected (HPIV3 or HPIV3ΔM) and mock-infected cells in monosome fraction. (C) Scatter plots of TPMs for cellular mRNA transcript in polysome fraction, presented as in A. (D) Density plots of the log 2fold change in TPM in polysome fraction, presented as in B.

Figure 5. Interactions between Paramyxovirus matrixes and the core components of exon junction complex.

(A) Protein complexes enriched in CORUM protein database from matrix interactome identified by MudPIT analysis. Adjusted P-value indicated the significance of the enriched protein complex. (B) HEK-293Ts overexpressing the indicated FLAG-tagged matrix proteins were Immunoprecipitated (+/- RNase) with Anti-FLAG M2 affinity gel after 48 hrs post-transfection. Matrix-bound proteins were analyzed by immunoblotting and endogenous levels of eIF4AIII, Y14, and MAGOH were detected by designated Abs. The amount of input was 5% of total IP lysates. (C) HEK-293Ts were subjected to HA-tag immunoprecipitation following inoculation

19

585   with HPIV3 containing none or HA-tagged matrix at 0.01 m.o.i at 48 hrs post-infection. (D)

586   Nuclear and cytoplasmic fractions from cells expressing specified FLAG-tagged matrix proteins

587   were subjected to FLAG immunoprecipitation. Subsequent immunoblotting identified

588   interacting proteins. Values below the blots represent the intensity ratios of eIF4AIII, Y14,

589   and MAGOH from cytoplasm to nucleus. β-Tubulin and Lamin A/C served as cytoplasmic and

590   nuclear fraction markers, respectively. IP, immunoprecipitation. IB, immunoblot.

591

592   **Figure 6. Subcellular localization of core EJC in HPIV3 infected HeLa cells.**

593   (A-B) Immunoblotting analysis of whole cell lysates, cytoplasmic, and nuclear fractions from

594   HPIV3-infected HeLa cells at 12- and 24-hours post-infection (hpi). The levels of eIF4AIII,

595   Y14, and MAGOH were examined, with β-tubulin and Lamin A/C serving as markers for the

596   purity of cytoplasmic and nuclear fractions, respectively. The ratios below the blots indicate

597   the relative intensities of eIF4AIII, Y14, and MAGOH from the cytoplasm to the nucleus. (C-

598   E) XYZ planes of 3D confocal micrographs depicted HeLa cells at 24 hours post-infection with

599   HPIV3 at m.o.i of 5. Cells were fixed and stained with (C) anti-eIF4AIII, (D) anti-Y14, or (E)

600   anti-MAGOH antibodies (red), and anti-HPIV3-M antibody (cyan) to label the viral matrix

601   protein. Nuclei were counterstained with Hoechst (blue), and GFP fluorescence indicates

602   HPIV3 infection. Enlarged orthogonal projections of the infected cells (white dashed line) are

603   shown on the right, displaying the EJC protein, HPIV3-M, and the merged channels. Scale

604   bars represent 20 μm. (F) Left: HeLa cells infected with either HPIV3 or HPIV3ΔM at an m.o.i.

605   of 5 were fixed at 24 hours post-infection and stained with anti-eIF4AIII (red), anti-HPIV3-M

606   antibodies (cyan), Hoechst for nuclei (blue), and GFP fluorescence indicates HPIV3 infection.

607   Representative fields of cells for each condition are shown. Right panel: Quantification of

608   cytoplasmic/nuclear eIF4AlII intensity (C: N) ratios was performed on 30 individual cells, as

609   described in Materials and Methods. Statistical significance was analyzed by unpaired t-test.

610   **** P <0.0001.

611

612   **Figure 7. Effects of paramyxoviral-matrix on Nipah-NPL replicon in eIF4AlII**

613   **knockdown cells.**

614   (A) HEK-293T cells were co-transfected with either control siRNA (siNC) or siRNA pool

615   targeting eIF4AIII (sieIF4AIII) along with an empty vector (EV) or plasmids NiV-M or HPIV3-

616   M 24 h. Following transfection, cells were inoculated with rNiV-NPL replicon virus-like particles

617   (VPL) and incubated for an additional 48 hours. Relative luciferase activity was measured

618   using the Nano-Glo HiBiT system (upper panel). Puromycin-pulsed cells were analyzed by

619   immunoblotting to assess protein expression levels (lower panel). (B-F) Total RNA was

620 extracted from cells treated as in (A) and subjected to RT-qPCR. Relative viral transcript

621 quantity (RQ) was normalized to GAPDH expression. Symbols are data points from biological

622 triplicates. Bar represents the mean ± SD. Statistical significance was determined by one-way

623 ANOVA with Dunnett multiple comparison test. * P <0.05; ** P <0.01; *** P <0.001; ****

624 P <0.0001; ns, not significant.

625

626 **Figure 8. Effects of the exon junction complex on Paramyxovirus, Influenza A,**

627 **Enterovirus D68, and SARS-CoV2 replication.**

628 HEK-293T cells were transfected with siRNA pools targeting eIF4A3**,** Y14, MAGOH, or non-

629 targeting control siRNAs (NC), respectively. At 48 hrs post-transfection, cells were inoculated

630 with the designated virus (A) HPIV3, (B) Cedar, (C) MuV, (D) NDV, (E) Influenza A

631 (A/WSN/1933), (F) Enterovirus D68, and (G) SARA-CoV2 at a multiplicity of infection (m.o.i.)

632 of 0.01. The titers of infectious supernatants were determined on Vero-CCL81 cells using a

633 10-fold serial dilution at the indicated time points. For each virus, the expression levels of

634 endogenous eIF4AIII, Y14, and MAGOH, along with infection control for viral protein or EGFP

635 reporter, were analyzed by immunoblotting; results shown beside each panel confirm the

636 knockdown of target proteins and validate virus infection. Symbols represent the data points

637 from biological triplicates. Bars represent the mean of the triplicates. Statistical significance

638 was determined by two-way ANOVA with Dunnett multiple comparison test. * P <0.05; ** P

639 <0.01; *** P <0.001; **** P <0.0001; ns, not significant. Immunoblottings are shown

640 beside each to determine the knockdown of target proteins and controls for virus infection.

641

642 **STAR METHODS**

643 **KEY RESOURCE TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-FLAG M2 antibody	Sigma-Aldrich	F3165
Anti-HA antibody	Sigma-Aldrich	H3663
Anti-HPIV3-N	This study	N/A
Anti-HPIV3-M	This study	N/A
Anti-eIF4AIll	Abcam	Ab180573
Anti-Y14	Abcam	Ab181038
Anti-MAGOH	Abcam	Ab180505
Anti-GFP	Cell Signaling	2956
Anti-S6 Ribosomal Protein	Cell Signaling	2217, 2317
Anti-L7a Ribosomal Protein	Cell Signaling	2415
Anti-GAPDH	Cell Signaling	2118
Anti-β-Actin	Cell Signaling	3700
Anti-β-Tubulin	Cell Signaling	2128
Anti-Lamin A/C	Cell Signaling	4777
Anti-COX IV	LI-COR	926-42214
Anti-Enterovirus D68 VP1	GeneTex	GTX125989
Anti-Influenza A Virus Nucleoprotein	GeneTex	GTX125989
Anti-SARS-CoV2-N	Dr. Thomas Moran	Clone:1C7
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	ThermoFisher	A21245
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	ThermoFisher	A21236
Bacterial and virus strains		
Recombinant rHPIV3-EGFP JS strain	PMID: 28405630	GenBank: KY295925
Recombinant rHPIV3-EGFP-HA-M JS strain	This study	N/A
Recombinant rHPIV3-EGFP-ΔM-mCherry JS strain	This study	N/A
Recombinant rHPIV3-EGFP-ΔM JS strain	This study	N/A
Recombinant rMuV-EGFP JL5 strain	PMID: 28405630	GenBank: KY295913
Recombinant rNDV-EGFP LaSota strain	PMID: 28405630	GenBank: KY295917
Recombinant rCedar-EGFP CG1a strain	This study	GenBank: JQ001776
EV D68 strain US/MO/14-18947	ATCC	VR1283
Influenza A virus strain A/WSN/33	PMID: 561860	N/A
SARS-CoV-2 strain USA/WA1	BEI resources	NR-52281
Max Efficiency Stbl2 competent cells	ThermoFisher	10268019
Chemicals, peptides, and recombinant proteins		
DMEM, high glucose, pyruvate	ThermoFisher	11995-065
Opti-MEM, Reduced Serum Medium	ThermoFisher	31985-070
Lipofectamine LTX and PLUS reagent	ThermoFisher	15338100
Lipofectamine RNAiMAX Transfection Reagent	ThermoFisher	13778100
BioT transfection reagent	Bioland Scientific	B01-01
Fetal Bovine Serum - Optima	R&D Systems	S12450
Fetal Bovine Serum - Tetracycline-free)	Takara	631101
Penicillin-Streptomycin	ThermoFisher	15140122
PBS	ThermoFisher	10010023

Trypsin-EDTA (0.25%)	ThermoFisher	2500-056
InFusion HD Cloning Kit	Takara Bio	639650
Paraformaldehyde 16% Aqueous Solution	Electron Microscopy Sciences	15710-S
Intercept Blocking Buffer	Li-COR	927-70001
Collagen I-coated coverslip	Neuvitro	GG-18-15-Collagen
Cycloheximide (CHX)	Sigma-Aldrich	C7698-1G
Triton X-100	Sigma-Aldrich	T8787
Diethiothreitol (DTT)	Sigma-Aldrich	D9779
Puromycin	ThermoFisher	A1113803
Zeocin	ThermoFisher	R25001
4–15% Mini-PROTEAN TGX Precast Protein Gels	Bio-Rad	4561083,4561086
Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit	Bio-Rad	1704272
ProLong Glass Antifade Mountant with NucBlue Stain	ThermoFisher	P36983
1M Tris-HCl pH 8.0	ThermoFisher	AM9855G
1M Tris-HCl pH 7.5	ThermoFisher	15567027
0.5M EDTA pH 8.0	ThermoFisher	15575020
5M NaCl	ThermoFisher	AM9760G
1M MgCl$_2$	ThermoFisher	AM9530G
2M KCl	ThermoFisher	AM9640G
RNaseOUT	ThermoFisher	10777019
Halt™ Protease Inhibitor Cocktail, EDTA-Free	ThermoFisher	78437
Trichloroacetic acid (TCA)	Sigma-Aldrich	T9159-100G
Anti-FLAG M2 affinity gel	Sigma-Aldrich	A2220
Anti-HA Magnetic Beads	ThermoFisher	88837
Critical commercial assays		
Direct-zol RNA miniprep kit	Zymo Research	R2050
Luna Universal qPCR Master Mix	NEB	M3003
LunaScript RT SuperMix Kit	NEB	E3010
Nano-Glo HiBit lytic detection system	Promega	N3040
ONE-Glo luciferase assay system	Promega	E6100
Deposited data		
Polysome profile mRNA sequencing data	This study	GSE274026
Experimental models: Cell lines		
HEK 293T	ATCC	Cat# CRL-3216
HeLa	ATCC	Cat# CCL-2
Vero	ATCC	Cat# CCL81
Vero-E6	ATCC	Cat# CRL-1586
RD	ATCC	Cat# CCL-136
Vero-HPIV3-Mpot	This study	N/A
BSR-T7	PMID: 9847328	N/A
BSR-T7-HPIV3-Mopt	This study	N/A
BSR-T7-rNiV-N-P-L replicon	This study	
Oligonucleotides		
See Table S1	This study	N/A
Recombinant DNA		
pCMV-3Tag-NiV-M	PMID: 21085610	N/A
pCMV-3Tag-HeV-M	PMID: 25782006	N/A
pCMV-3Tag-GhV-M	PMID: 25782006	N/A

pCMV-3Tag-SeV-M	PMID: 25782006	N/A
pCMV-3Tag-MuV-M	PMID: 25782006	N/A
pCMV-3Tag-MeV-M	PMID: 25782006	N/A
pCMV-3Tag-HPIV2-M	PMID: 25782006	N/A
pCMV-3Tag-NDV-M	PMID: 25782006	N/A
pCMV-3Tag-HPIV3-M	This study	N/A
pCMV-3Tag-CedV-M	This study	N/A
pCMV-3Tag-GFP-NiV-M	PMID: 21085610	N/A
pCMV-3Tag-GFP-NiV-M Mbp1/2	PMID: 21085610	N/A
pCMV-3Tag-GFP-NiV-M L106A, L107A	PMID: 21085610	N/A
pFLAG-CMV2-GFP-HPIV3-M	This study	N/A
pFLAG-CMV2-GFP-HPIV3-M Mbp1/2	This study	N/A
pFLAG-CMV2-GFP-HPIV3-M L106A, L107A	This study	N/A
pCAGGS-HPIV3-N	This study	N/A
pCAGGS-HPIV3-P	This study	N/A
pCAGGS-HPIV3-M	This study	N/A
pCAGGS-HPIV3-F	This study	N/A
pCAGGS-HPIV3-HN	This study	N/A
pCAGGS-HPIV3-L	This study	N/A
pCMV-LUC2CP/intron/ARE	Addgene	#62858
pCW57.1	Addgene	#41393
pCW57.1		
Software and algorithms		
Prism	GraphPad	Version 10
SnapGene	SnapGene.com	Version 4.2.11
Image Lab	Bio-Rad	Version 6.1
Partek Flow	Partek	Version 10
Imaris	Oxford Instruments	Version 9
Celigo Imaging Software	Nexcelom	Version 5.5
Other		
Celigo Imaging Cytometer	Nexcelom	N/A
Gradient Mate Station	Biocomp	N/A
Piston gradient fractionator	Biocomp	N/A
EVOS M5000	ThermoFisher	N/A
ChemiDoc MP Imaging system	Bio-Rad	N/A
CFX96 Real-Time PCR system	Bio-Rad	N/A

644

645 **RESOURCE AVAILABILITY**

646 **Lead Contact**

647 Further information and requests for resources and reagents should be directed to and will

648 be fulfilled by the lead contact, Dr. Benhur Lee (benhur.lee@mssm.edu)

649

650 **Materials Availability**

651 Reagents are available from the lead contact at request.

652 **Data and Code Availability**

653 • The raw and analyzed for RNA-sequencing is accessible at NCBI GEO under the

654 accession number GSE274026.

655 • This paper does not report original code.

656

657 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

658

659 **Cell lines.**

660 HEK 293T (Human embryonic kidney), HeLa cells (Human cervical carcinoma), RD cells

661 (Human Rhabdomyosarcoma), Vero cells (African Green monkey kidney), Vero-E6 cells (Clone

662 E6 from African Green monkey kidney) and BSR-T7 cells (a derivative of BHK-21, Syrian

663 golden hamster kidney) were all maintained at 37°C in a 5% CO_2 in Dulbecco's modified

664 Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 100X

665 penicillin/streptomycin solution (ThermoFisher). For confocal microscopy imaging, HeLa cells

666 were seeded on an 18 mm #1.5 collagen I-coated coverslip (Neuvitro). For plasmid

667 transfection, cells were transfected using Lipofectamine LTX per the manufacturer's

668 instructions (ThermoFisher). To generate cells with doxycycline-inducible expression of HPIV3

669 matrix, cDNA encoding codon optimized HPIV3-M was inserted into pCW57.1 (Addgene,

670 #41393) through *NheI* and *AgeI* sites. Lentivirus encoding HPIV3-M was produced by co-

671 transfecting HEK293T cells with pCMV-VSV-G, psPAX2, and pCW57.1-HPIV3-M. At 48 hours

672 post-transfection, the supernatants were collected and centrifuged at 800 x g to remove cell

673 debris. BSR-T7 and Vero cells were transduced with pCW57.1-HPIV3-M lentivirus. At 48 hours

674 post-transduction, the cells were selected with 10 μg/mL puromycin (ThermoFisher,

675 A1113803) in DMEM contain 10% tetracycline-free FBS.

676

677 **Viruses**

678 Recombinant viruses contain HPIV3 JS strain (GenBank: KY295925), Cedar CG1a (GenBank:

679 JQ001776), MuV JL5 strain (GenBank: KY295913), and NDV LaSota strain (GenBank:

680 KY295917) were propagated in Vero cells maintained in DMEM medium supplemented with

681 10% FBS. EV D68 strain US/MO/14-18947 (ATCC, VR-1823) were amplified in RD cells.

682 Influenza A virus strain A/WSN/33 (ATCC, VR-1520) was propagated in embryonic eggs.

683 SARS-CoV-2 strain USA/WA1 (BEI resources, NR-52281) was amplified in Vero-E6 cells.

684

685 **METHOD DETAILS**

686

687 **Virus inoculation and titration**

688   For infection, cells were inoculated at the designated multiplicity of infection (m.o.i.) in serum-

689   free DMEM. The virus was allowed to adsorb at 37°C for 1 hour, after which cells were washed

690   with phosphate-buffered saline (PBS) and incubated at 37°C in a medium containing 10%

691   FBS. At specific time points post-infection, the supernatant was harvested for titration, and

692   cells were washed with PBS for cell lysate or RNA extractions. Titrations of HPVI3, Cedar, MuV,

693   and NDV stocks were performed on Vero cells in a 96-well format, with individual infection

694   events (infectious units, IU/mL) identified by GFP fluorescence at 24 hours post-infection

695   using a Celigo Imaging Cytometer (Nexcelom). Plaque assay is utilized for the titration of EV

696   D68, Influenza A, and SARS-CoV-2.

697

698   **Plasmids and reverse genetic constructs**

699   Cloning of codon-optimized 3X-Flag-tagged Nipah virus matrix (NiV-M), Hendra virus (HeV-

700   M), Ghana virus (GhV-M), Sendai virus (SeV-M), Mumps virus (MuV-M), Measles virus (MeV-

701   M), Human Parainfluenza Viruses 2 (HPIV2-M) and Newcastle disease virus M (NDV-M) is

702   described in [14,16]. We similarly codon optimized and cloned the open reading frames encoding

703   M from Human Parainfluenza Viruses 3 (HPIV3-M) and Cedar virus (CedV-M), fragments were

704   inserted within the *HindIII* and *XhoI* sites of pCMV-3Tag-1. For constructing Flag-GFP-tagged

705   HPIV3-M, EGFP was fused to the N-terminus of M by overlapping PCR, and the cDNAs were

706   then in-frame inserted at the *EcoRI* and *EcoRV* sites of pFLAG-CMV2. Alignment of HPIV3-M

707   sequences using Clustal Omega identified sequence motifs corresponding to NiV-M's nuclear

708   export sequence (NES) and bipartite nuclear localization sequence (BpNLS) [16]. Mutations were

709   generated using overlap extension PCR. For Flag-tagged HPIV3 viral proteins, cDNA from

710   HPIV3 nucleocapsid (N), phosphate (P), matrix (M), fusion protein (F), receptor binding

711   protein (HN) and polymerase (L) were PCR fused with Flag-tag at either N- (M and P) or C-

712   terminus (N, F, HN and L), the fragments were inserted at the *EcoRI* and *NheI* sites of pCAGGS.

713   We modified the rHPIV3-JS construct to generate the rHPIV3-HA-M virus by inserting a HA

714   tag at the N-terminus of the matrix protein. Additionally, we constructed the rHPIV3ΔM-

715   mCherry and rHPIV3ΔM viruses by introducing mCherry cDNA between the P and F genes to

716   replace the coding sequence of M or by deleting the coding sequence of M altogether.

717

718   **Recovery of rHPIV3ΔM-mCherry and rHPIV3ΔM viruses from cDNA**

719   For virus rescue, 4×10^5 doxycycline-inducible BSR-T7 cells expressing HPIV3-M per well

720   were seeded into a 6-well format and induced to express HPIV3-M with 500 ng/mL doxycycline

721   The following day, transfection reactions were performed as previously described [67] with the

722   plasmid encoding the antigenomic sequence of rHPIV3ΔM-mCherry or rHPIV3ΔM. The

26

723 recovery of viruses was monitored (Figure S8) using EVOS M5000 imaging system
724 (ThermoFisher); recombinant rHPIV3ΔM-mCherry and rHPIV3ΔM viruses were then amplified
725 in doxycycline-inducible Vero cells expressing HPIV3-M.

726

727 **Cloning of a rNiV N-P-L Replicon**

728 The rNiV N-P-L replicon was constructed using a combination of PCR, overlap extension PCR,
729 and InFusion cloning, based on our previously described full-length rNiV$_{Mal}$ GLuc-P2A-eGFP
730 reverse genetics plasmid[68]. First, the rNiV$_{Mal}$ GLuc-P2A-eGFP construct was digested with *MluI-*
731 *HF* and *AgeI-HF* overnight, followed by gel purification of the vector. InFusion cloning was
732 then employed to re-integrate the removed NiV sequence and to incorporate a codon-
733 optimized HiBiT-tagged eGFP reporter gene (Twist Biosciences). Next, this intermediate
734 construct was digested with *PacI-HF* and *BsiWI-HF* restriction enzymes. Using overlap
735 extension PCR and InFusion cloning, we restored the NiV-P gene and inserted a PuroR-P2A-
736 BleoR gene in place of the NiV-M gene. Downstream of the integrated PuroR-P2A-BleoR gene,
737 we maintained the NiV-M 3' UTR up to the NiV-M gene end signal and intergenic 'CTT' motif.
738 Immediately following the 'CTT' intergenic sequence, we appended the 5' UTR of the NiV-L
739 gene, starting from the NiV-L gene start signal, and restored the sequence of NiV-L through
740 the *BsiWI* restriction site. This cloning strategy ensured that each encoded viral gene retained
741 its native 3' and 5' UTRs.

742

743 **Generating rNiV N-P-L replicon stable cells**

744 To generate rNiV N-P-L replicon stable cells, we followed an adapted protocol as previously
745 described [67]. 3.8×10^5 BSR-T7 cells per well were seeded into a 6-well format. The following
746 day, cells were transfected with the plasmid encoding the antigenomic sequence of the N-P-
747 L replicon. Cells were monitored daily for GFP-positive signals. At 72 hrs post-transfection,
748 the cells were trypsinized and transferred to a T75 flask containing 5.0 µg/mL of puromycin
749 (ThermoFisher, A1113803). This selection pressure was maintained until most GFP-negative
750 cells had died. After 5 days, the medium was replaced with 150 µg/mL of zeocin, and the cells
751 were further cultured in zeocin (ThermoFisher, R25001) until GFP-positive colonies appeared.
752 The bulk GFP-positive population was then passaged in the presence of Zeocin and/or
753 puromycin to ensure the stability and selection of the replicon-containing cells.

754

755 **Deriving rNiV N-P-L replicon VLPs**

756 To generate rNiV N-P-L replicon viral-like particles (VLPs), 3.8×10^5 cells of the BSRT7 cells
757 containing the rNiV N-P-L replicon were seeded into a 6-well format. The following day, the

758   cells were transfected using a 1:1:1 ratio of AU1-tagged NiV-F, HA-tagged NiV-G, and

759   untagged NiV-M plasmids. Transfection complexes were prepared by diluting 0.67 µg each of

760   NiV-F, NiV-G, and NiV-M in 200 µL of DMEM, followed by the addition of 3 µL of BioT

761   transfection reagent (Bioland Scientific, B01-01). After a 10 min incubation at room

762   temperature, the transfection complexes were added dropwise to the cells. The cells were

763   monitored for syncytia formation, with media changes every 48 hr. At 5 days post-transfection,

764   when most of the monolayer had fused, the supernatant was collected and clarified by

765   centrifugation at 800 x g for 10 min. The clarified supernatant was then aliquoted and frozen

766   at -80°C until further use.

767

768   **siRNA depletion of host factors**

769   For siRNA depletions, cells were treated with siRNAs against eIF4AIII, Y14, and MAGOH

770   (FlexiTube siRNA, QIAGEN) or non-targeting siRNA (Sigma-Aldrich) in a pool format (mixture

771   of 3 siRNA targeting a single gene) for 48 h. Lipofectamine RNAiMAX (ThermoFisher,

772   13778100) (3.4 µL), Opti-mem (200 µL), and siRNA pool (2 µL) were mixed and incubated

773   for 20 min at room temperature, then reverse transfections were performed in 12 well plates

774   with 4 x 10^5 HEK 293T cells per well at a final concentration of 20 nM siRNA.

775

776   **Immunoprecipitation and immunoblotting**

777   For Flag or HA tag protein immunoprecipitation, cells were harvested using lysis buffer (50

778   mM Tris–HCl, pH 7.4, with 150 mM NaCl, 1 mM EDTA, and 1% Triton-X-100), samples were

779   placed on ice for 30 min, centrifuged at 12 000 × g for 30 min. Fixed amounts of cell lysate

780   were subsequently incubated with Anti-FLAG M2 affinity gel (Sigma-Aldrich, A2220) or Anti-

781   HA Magnetic Beads (ThermoFisher, 88837) overnight at 4°C. The reactants were washed five

782   times with wash buffer (50 mM Tris–HCl, pH 7.4, with 150 mM NaCl) and the

783   immunoprecipitation complex was eluted by 2× sample buffer (125 mM Tris–HCl, pH 6.8, with

784   4% SDS, 20% (v/v) glycerol, and 0.004% bromophenol blue at 90°C for 5 min. The eluate

785   proteins were subjected to immunoblot analysis. All protein samples were run under reduced

786   conditions in 1x sample buffer containing 100 mM dithiothreitol (DTT, Sigma-Aldrich, D9779).

787   Samples were incubated in a heating block at 95°C for 10 min, resolved in a 4 to 15% SDS-

788   PAGE gel (Bio-Rad, 4561083), and transferred to polyvinylidene difluoride (PVDF) membranes

789   (Bio-Rad, 1704272). Membranes were blocked with phosphate-buffered saline blocking buffer

790   (LI-COR; 927-700001) and then probed with the indicated antibodies. Antibodies against

791   FLAG (Sigma-Aldrich, F3165), HA (Sigma-Aldrich, H3663), EGFP (Cell signaling, 2956),

792   HPIV3-N (Benhur Lee), HPIV3-M (Benhur Lee), eIF4AlII (Abcam, ab180573), Y14 (Abcam,

28

793 2956), MAGOH (Abcam, ab180505), S6 (Cell signaling, 2217 and 2317), L7a (Cell signaling,

794 2415), GAPDH (Cell signaling, 2118), Actin (Cell signaling, 3700), Beta-tubulin (Cell signaling,

795 2128), Lamin A/C (Cell signaling, 4777), COX IV (LI-COR, 926-42214), EV D68 VP1(GeneTex,

796 GTX132313), SARS-CoV2-N (1C7 from Thomas Moran) and Influenza A virus Nucleoprotein

797 (GeneTex, GTX125989) were used. Membranes were washed and probed with Alexa Fluor

798 647-conjugated anti-mouse or anti-rabbit (ThermoFisher, A21245 and A21236). The signal

799 of Alexa Fluor 647 was detected using the ChemiDoc MP imaging system (Bio-Rad). Relative

800 puromycylated protein abundance was calculated by first normalizing abundance relative to

801 Actin expression and then normalization to either mock infection or empty vector. In

802 cytoplasmic-nuclear fractionation, relative cEJC protein abundance in each fraction was

803 calculated by first normalizing abundance relative to the expression of the fraction marker

804 Lamin A/C or beta-tubulin and then calculated the cytoplasm to nucleus ratios.

805

806 **Immunofluorescence microscopy and image analysis**

807 Cells were washed with PBS and fixed with 4% formaldehyde for 20 min at room temperature.

808 Fixed cells were permeabilized in a blocking buffer containing PBS, 0.5% Triton X-100, and

809 1% BSA. After incubation with antibodies/probes in blocking buffer, samples were washed in

810 blocking buffer and mounted on glass slides with ProLong glass antifade mountant with

811 NucBlue stain (ThermoFisher, P36983). The slides were imaged on a Zeiss LSM 880 confocal

812 microscope, acquiring (or without) optical Z-stacks of 0.3–0.5 µm steps. HPIV3-M was

813 detected with rabbit anti-HPIV3-M antibodies (1:200), and cEJC was detected with rabbit anti-

814 eIF4AlII, Y14, and MAGOH antibodies (1:500). Alexa-fluor conjugated Anti-IgG antibodies of

815 appropriate species reactivity and fluorescence spectra were used for secondary detection

816 (1:1000) (ThermoFisher). To determine the quantity of matrix, image analysis was performed

817 with Imaris from Oxford instrument using the multicomponent detection module, cytoplasm

818 and nucleus mean intensities for matrix were acquired. The statistical analysis involved

819 calculating the ratio of the mean cytoplasmic region intensity to the mean nuclear region

820 intensity for each cell. Given that the cytoplasmic/nuclear fluorescent intensity (C: N) ratio

821 for the wild-type (WT) matrix is close to 1, C: N ratios greater than 1 imply increased

822 cytoplasmic retention whereas C: N ratios less than 1 indicate increased nuclear retention.

823 Between 30-50 cells were counted for each condition.

824

825 **Polysome profiling**

826 For polysome profiling, a 10-cm dish of HEK-293Ts was mock-infected or infected at a

827 multiplicity of infection of 5 with HPIV3 for 48 hrs. Cells were treated with 100 µg/mL

828   cycloheximide (CHX, Sigma-Aldrich, C7698) for 5 min at 37°C, then washed with cold PBS
829   containing 100 μg/mL CHX. Cells were scraped into a 15 mL centrifuge tube and pelleted at
830   300 × g for 10 min. Cells were resuspended in 1 mL polysome lysis buffer (20 mM Tris-HCl
831   pH 8.0, 100 mM KCl, 5 mM MgCl2, 1% (v/v) Triton-X100, 100 μg/ml CHX, 1mM DTT, 2U/ μL
832   RNaseOUT and 1X EDTA-free protease inhibitor), vortexed briefly, and incubated on ice for
833   15 min. Later, cells were subjected to 5–7 passages through a 26-gauge syringe followed by
834   centrifugation at 4°C for 10,000 x g for 20 min, and the clarified lysates were used for gradient
835   sedimentation analysis. Sucrose gradient was prepared via a Gradient Mate Station (Biocomp)
836   using 10% and 50% sucrose dissolved in polysome buffer (20 mM Tris-HCl pH 8.0, 100 mM
837   KCl, 5 mM MgCl2, and 1X EDTA-free protease inhibitor). 30 OD of lysate was resolved on a
838   10–50% (wt/vol) sucrose gradient by centrifugation at 40,000 rpm at 4 °C for 150 min in a
839   Beckman SW41-Ti rotor. 600 μL fractions were collected from the top of the gradient while
840   monitoring absorbance at λ = 254 nm on a piston gradient fractionator (Biocomp). Total RNA
841   was extracted from cells using a Direct-zol RNA miniprep kit (Zymo Research) and protein
842   was trichloroacetic acid (TCA) precipitated and analyzed by immunoblotting.

843

844   **RNA extraction, RNA-Seq, and gene expression analysis**
845   Total RNA was extracted polysome and monosome fractions using a Direct-zol RNA miniprep
846   kit (Zymo Research) according to the manufacturer's protocol. Polyadenylated RNA
847   enrichment, RNA-seq library preparation, and sequencing process were conducted at Azenta
848   Life Sciences (South Plainfield, NJ, USA). Sequencing libraries were sequenced on an Illumina
849   HiSeq platform (2x150bp, ~350M pair-end reads). Gene expression analysis was performed
850   on Partek Flow (Partek), reads were trimmed and mapped to the hg38 and rHPIV3-JS
851   genomes, and Transcripts per Kilobase Million (TPM) were calculated for genes with mapped
852   reads in all the fractions of both uninfected and infected cells using the total number of
853   mapped exons reads. Density analysis was performed in python using kernel density
854   estimation.

855

856   **Reverse transcription and real-time quantitative PCR (RT–qPCR)**
857   Total RNA was extracted using the Direct-zol RNA Miniprep Kit (Zymo Research, R2050).
858   Equivalent amounts of total RNA were reverse transcribed using either oligo(dT) primers or
859   viral genome-specific primers with the LunaScript RT Master Mix Kit (NEB, E3010).
860   Quantitative PCR (qPCR) was performed with gene-specific primers (Table S1) and Luna
861   Universal qPCR Master Mix (NEB, M3003) on the Bio-Rad CFX96 Real-Time PCR system
862   (Bio-Rad). The relative RNA levels of specific targets were normalized to GAPDH or 18S

863 rRNA and calculated using the comparative threshold cycle (ΔΔCT) method.

864

865 **QUANTIFICATION AND STATISTICAL ANALYSIS**

866 One-way and two-way ANOVA were used to estimate statistical significance among multiple

867 groups and conditions, while an unpaired t-test was applied for comparisons between two

868 groups. Data are presented as mean ± standard deviation (SD) with biological triplicates. A

869 P-value of ≤0.05 was considered statistically significant, with significance levels indicated as

870 follows: * P≤0.05; ** P≤0.01; *** P≤0.001; **** P≤0.0001; NS, not significant. Statistical

871 analyses were performed using Prism 10 software (GraphPad Software).

872

873

874 <u>**SUPPLEMENTAL INFORMATION TITLES AND LEGENDS**</u>

875

876 **Supplemental information**

877 Document S1. Figures S1-S8 and Table S1

878 Data S1. Excel file containing data too large to fit in a PDF, related to Figure 3

879 Data S2. Excel file containing data too large to fit in a PDF, related to Figure 4

880

881 **Figure S1. Mutagenesis studies of nuclear localization signals (NLSs) and nuclear**

882 **export signals (NESs) in GFP fused HPIV3-M and NiV-M.**

883 (A) Positively charged amino acid residues in the bipartite NLSs or key leucine residues in the

884 potential NESs were mutated to alanine. (B) HeLa cells expressing either wild-type (WT), NLS

885 mutant (Mbp1/2), or NES mutant (L106A L107A) forms of GFP-fused HPIV3-M and NiV-M

886 were fixed and stained with Hoechst to visualize nuclei. Representative fields of cells

887 expressing each construct are shown. Scale bars represent 20 μm (C) Quantification of the

888 cytoplasmic/nuclear GFP intensity (C: N) ratios for 30–50 individual cells was analyzed for

889 each mutant, as described in the Materials and Methods. Statistical significance was

890 determined by one-way ANOVA with Dunnett's multiple comparison test. **** P < 0.0001.

891

892 **Figure S2. Effects of HPIV3 infection and matrix protein on host translational profile.**

893 (A) Polysome profiles of mock-infected (black), HPIV3 infected (blue), or HPIV3-M transfected

894 (red) HEK-293Ts at 48 hrs post-infection. HEK-293Ts were infected with HPIV3 (MOI of 5) or

895 transfected with matrix for 48 hrs and cytoplasmic extracts were prepared for polysome

896 profiling. Cytoplasmic extracts were sedimented through a 10–50% sucrose gradient and 0.6

897 ml fractions were collected while continuously measuring absorbance at λ = 254nm. (B)

898 Proteins were TCA precipitated from the collected fraction with equal volume and analyzed by

899 immunoblotting to determine the sedimentation of S6, L7a, eIF4AIII, Y14, MAGOH, and HPIV3-

900 M with ribosomal subunits, monosomes, or polysomes. (C-D) Densitometric quantification of

901 the indicated proteins (S6 and L7a) across 16 fractions from (B). The y-axis shows the

902 percentage of the total integrated intensity (% of Total Int) for each protein in the indicated

903 condition: mock infection (black), HPIV3 infection (blue), and HPIV3 matrix protein expression

904 (red).

905

906 **Figure S3. Nuclear-cytoplasmic trafficking of HPIV3 matrix protein (HPIV3-M)**
907 **during infection.**

908 (A) HeLa cells infected with HPIV3 at m.o.i of 5 and then incubated with fresh growth medium

909 for up to 24 hrs. At 12, 16, 20, and 24 hours of post-infection, cells were fixed and

910 counterstained with anti-HPIV3-M antibody (red) to label viral matrix protein, and nuclei were

911 stained with Hoechst (blue). Representative fields of cells at each time point are shown. Scale

912 bars represent 20 µm (B) Quantification of cytoplasmic/nuclear HPIV3-M intensity (C: N)

913 ratios was performed on 30–50 individual cells, as described in the Materials and Methods.

914 Statistical significance was analyzed by one-way ANOVA with Dunnett. **** P <0.0001; ns,

915 not significant.

916

917 **Figure S4. Effects of the exon junction complex on Paramyxovirus infection.**

918 HEK-293T cells were transfected with siRNA pools targeting eIF4A3**,** Y14, MAGOH, or non-

919 targeting control siRNAs (NC), respectively. At 48 hrs post-transfection, cells were inoculated

920 with the designated virus (A) HPIV3, (B) Cedar, (C) MuV, and (D) NDV at a multiplicity of

921 infection (m.o.i.) of 0.01. The number of GFP-positive cells in each well was acquired at the

922 indicated time points by Celigo imaging cytometer (Nexcelom). Relative fold changes (FC) in

923 GFP-positive cells per well were then calculated. Symbols represent the data points from

924 biological triplicates. Bars represent the mean of the triplicates. Statistical significance was

925 determined by two-way ANOVA with Dunnett multiple comparison test. * *P* <0.05; ** *P* <0.01;

926 *** *P* <0.001; **** *P* <0.0001; ns, not significant.

927

928 **Figure S5. Subcellular localization of eIF4AIII in HeLa cells expressing GFP fused**
929 **HPIV3 matrixes.**

930 Left panel HeLa cells expressing either wild-type (WT), NLS mutant (Nbp1/2), or NES mutant

931 (L106A L107A) forms of GFP-fused HPIV3-M and NiV-M were fixed and stained with anti-

932 eIF4AIII (red) and Hoechst for nuclei (blue), and GFP fluorescence indicates M expression.

933 Representative fields of cells for each condition are shown. Scale bars represent 20 μm. Right

934 panel: Quantification of cytoplasmic/nuclear eIF4AIII intensity (C: N) ratios was performed on

935 30 individual cells, as described in Materials and Methods. Statistical significance was analyzed

936 by one-way ANOVA with Dunnett multiple comparison test. **** *P* <0.0001; ns, not

937 significant.

938

939 **Figure S6. Effects of HPIV3 infection on NMD activity.**

940 HEK-293T cells infected with HPIV3 at m.o.i of 0.01 and analyzed at 24 and 48 hours of post-

941 infection. Endogenous targets of the NMD mRNA surveillance pathway, SC35, GABARAPL1,

942 ASNS, and CARS were analyzed by quantitative RT-PCR. Relative quantification (Gene/GAPDH)

943 is normalized to uninfected controls. Symbols are data points from biological triplicates. Bar

944 represents the mean ± SD. Statistical significance was determined by one-way ANOVA with

945 Dunnett multiple comparison test. * P <0.05; **** P <0.0001; ns, not significant.

946

947 **Figure S7. Effects of HPIV3 matrix on NMD activity.**

948 HEK-293T cells were transfected with the indicated protein and analyzed at 24 and 48 hrs

949 post-transfection. Endogenous targets of the NMD mRNA surveillance pathway, SC35,

950 GABARAPL1, ASNS, and CARS were analyzed by quantitative RT-PCR. Relative quantification

951 (Gene/GAPDH) is normalized to uninfected controls. Symbols are data points from biological

952 triplicates. Bar represents the mean ± SD. Statistical significance was determined by two-

953 way ANOVA with Bonferroni's multiple comparisons test. ns, not significant.

954

955 **Figure S8. Recovery of rHPIV3ΔM-mCherry and rHPIV3ΔM viruses in BSR-T7 cells.**

956 Representative images from the rescue of (A) rHPIV3ΔM-mCherry and (B) rHPIV3ΔM at day

957 3 of post-transfection in BSR-T7 cells. Images were captured by EVOS m5000.

958

959 **Table S1: qPCR primers, related to Star Methods.**

960

961 **Data S1: Mapped viral read counts of polysome profile mRNA sequencing for**

962 **HPIV3-WT and HPIV3-delta-M virus.**

963 Tab 1: TPM normalized viral genes expression for HPIV3-WT and HPIV3-delta-M virus.

964 Tab 2: Ribosome association efficiency of viral transcripts for HPIV3-WT and HPIV3-delta-M

965 virus.

966

967 **Data S2. Mapped read count of polysome profile mRNA sequencing for Mock,**

968 **HPIV3-WT and HPIV3-delta-M samples.**

REFERENCE

1. Plemper, R.K., and Lamb, R.A. (2020). Paramyxoviridae: The Viruses and Their Replication. Fields virology. 7th ed (Lippincott Williams & Wilkins).
2. Henrickson, K.J. (2003). Parainfluenza viruses. Clin Microbiol Rev *16*, 242-264. 10.1128/CMR.16.2.242-264.2003.
3. Moscona, A. (2005). Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest *115*, 1688-1698. 10.1172/JCI25669.
4. Weinberg, G.A., Hall, C.B., Iwane, M.K., Poehling, K.A., Edwards, K.M., Griffin, M.R., Staat, M.A., Curns, A.T., Erdman, D.D., Szilagyi, P.G., and New Vaccine Surveillance, N. (2009). Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr *154*, 694-699. 10.1016/j.jpeds.2008.11.034.
5. Schomacker, H., Schaap-Nutt, A., Collins, P.L., and Schmidt, A.C. (2012). Pathogenesis of acute respiratory illness caused by human parainfluenza viruses. Curr Opin Virol *2*, 294-299. 10.1016/j.coviro.2012.02.001.
6. Linster, M., Do, L.A.H., Minh, N.N.Q., Chen, Y., Zhe, Z., Tuan, T.A., Tuan, H.M., Su, Y.C.F., van Doorn, H.R., Moorthy, M., and Smith, G.J.D. (2018). Clinical and Molecular Epidemiology of Human Parainfluenza Viruses 1-4 in Children from Viet Nam. Sci Rep *8*, 6833. 10.1038/s41598-018-24767-4.
7. Hetrich, M.K., Oliva, J., Wanionek, K., Knoll, M.D., Lamore, M., Esteban, I., Veguilla, V., Dawood, F.S., Karron, R.A., Epidemiology, S.A.-C.-., and Response in Children Study, T. (2023). Epidemiology of Human Parainfluenza Virus Type 3 and Respiratory Syncytial Virus Infections in the Time of Coronavirus Disease 2019: Findings From a Household Cohort in Maryland. Clin Infect Dis *76*, 1349-1357. 10.1093/cid/ciac942.
8. Takimoto, T., and Portner, A. (2004). Molecular mechanism of paramyxovirus budding. Virus Res *106*, 133-145. 10.1016/j.virusres.2004.08.010.
9. Harrison, M.S., Sakaguchi, T., and Schmitt, A.P. (2010). Paramyxovirus assembly and budding: building particles that transmit infections. Int J Biochem Cell Biol *42*, 1416-1429. 10.1016/j.biocel.2010.04.005.
10. El Najjar, F., Schmitt, A.P., and Dutch, R.E. (2014). Paramyxovirus glycoprotein incorporation, assembly and budding: a three way dance for infectious particle production. Viruses *6*, 3019-3054. 10.3390/v6083019.
11. Duan, Z., Li, Q., He, L., Zhao, G., Chen, J., Hu, S., and Liu, X. (2013). Application of green fluorescent protein-labeled assay for the study of subcellular localization of Newcastle disease virus matrix protein. J Virol Methods *194*, 118-122. 10.1016/j.jviromet.2013.08.014.
12. Duan, Z., Song, Q., Wang, Y., He, L., Chen, J., Zhu, Y., Hu, S., and Liu, X. (2013). Characterization of signal sequences determining the nuclear export of Newcastle disease virus matrix protein. Arch Virol *158*, 2589-2595. 10.1007/s00705-013-1769-5.
13. Peeples, M.E. (1988). Differential detergent treatment allows immunofluorescent localization of the Newcastle disease virus matrix protein within the nucleus of infected cells. Virology *162*, 255-259. 10.1016/0042-6822(88)90418-7.
14. Pentecost, M., Vashisht, A.A., Lester, T., Voros, T., Beaty, S.M., Park, A., Wang, Y.E., Yun, T.E., Freiberg, A.N., Wohlschlegel, J.A., and Lee, B. (2015). Evidence for ubiquitin-regulated nuclear and subnuclear trafficking among Paramyxovirinae matrix proteins. PLoS Pathog *11*, e1004739. 10.1371/journal.ppat.1004739.
15. Coleman, N.A., and Peeples, M.E. (1993). The matrix protein of Newcastle disease virus localizes to the nucleus via a bipartite nuclear localization signal. Virology *195*, 596-607. 10.1006/viro.1993.1411.
16. Wang, Y.E., Park, A., Lake, M., Pentecost, M., Torres, B., Yun, T.E., Wolf, M.C., Holbrook, M.R., Freiberg, A.N., and Lee, B. (2010). Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog *6*, e1001186. 10.1371/journal.ppat.1001186.

17. McLinton, E.C., Wagstaff, K.M., Lee, A., Moseley, G.W., Marsh, G.A., Wang, L.F., Jans, D.A., Lieu, K.G., and Netter, H.J. (2017). Nuclear localization and secretion competence are conserved among henipavirus matrix proteins. J Gen Virol *98*, 563-576. 10.1099/jgv.0.000703.

18. Ringel, M., Heiner, A., Behner, L., Halwe, S., Sauerhering, L., Becker, N., Dietzel, E., Sawatsky, B., Kolesnikova, L., and Maisner, A. (2019). Nipah virus induces two inclusion body populations: Identification of novel inclusions at the plasma membrane. PLoS Pathog *15*, e1007733. 10.1371/journal.ppat.1007733.

19. Ringel, M., Behner, L., Heiner, A., Sauerhering, L., and Maisner, A. (2020). Replication of a Nipah Virus Encoding a Nuclear-Retained Matrix Protein. J Infect Dis *221*, S389-S394. 10.1093/infdis/jiz440.

20. Gunther, M., Bauer, A., Muller, M., Zaeck, L., and Finke, S. (2020). Interaction of host cellular factor ANP32B with matrix proteins of different paramyxoviruses. J Gen Virol *101*, 44-58. 10.1099/jgv.0.001362.

21. Peng, T., Qiu, X., Tan, L., Yu, S., Yang, B., Dai, J., Liu, X., Sun, Y., Song, C., Liu, W., et al. (2022). Ubiquitination on Lysine 247 of Newcastle Disease Virus Matrix Protein Enhances Viral Replication and Virulence by Driving Nuclear-Cytoplasmic Trafficking. J Virol *96*, e0162921. 10.1128/JVI.01629-21.

22. Donnelly, C.M., Vogel, O.A., Edwards, M.R., Taylor, P.E., Roby, J.A., Forwood, J.K., and Basler, C.F. (2023). Henipavirus Matrix Protein Employs a Non-Classical Nuclear Localization Signal Binding Mechanism. Viruses *15*. 10.3390/v15061302.

23. Ding, B., Zhang, L., Li, Z., Zhong, Y., Tang, Q., Qin, Y., and Chen, M. (2017). The Matrix Protein of Human Parainfluenza Virus Type 3 Induces Mitophagy that Suppresses Interferon Responses. Cell Host Microbe *21*, 538-547 e534. 10.1016/j.chom.2017.03.004.

24. Bharaj, P., Wang, Y.E., Dawes, B.E., Yun, T.E., Park, A., Yen, B., Basler, C.F., Freiberg, A.N., Lee, B., and Rajsbaum, R. (2016). The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to Inhibit the IKKepsilon Kinase-Mediated Type-I IFN Antiviral Response. PLoS Pathog *12*, e1005880. 10.1371/journal.ppat.1005880.

25. Watkinson, R.E., and Lee, B. (2016). Nipah virus matrix protein: expert hacker of cellular machines. FEBS Lett *590*, 2494-2511. 10.1002/1873-3468.12272.

26. Wang, X., Zhu, J., Zhang, D., and Liu, G. (2022). Ribosomal control in RNA virus-infected cells. Front Microbiol *13*, 1026887. 10.3389/fmicb.2022.1026887.

27. Jaafar, Z.A., and Kieft, J.S. (2019). Viral RNA structure-based strategies to manipulate translation. Nat Rev Microbiol *17*, 110-123. 10.1038/s41579-018-0117-x.

28. Walsh, D., and Mohr, I. (2011). Viral subversion of the host protein synthesis machinery. Nat Rev Microbiol *9*, 860-875. 10.1038/nrmicro2655.

29. Schubert, K., Karousis, E.D., Jomaa, A., Scaiola, A., Echeverria, B., Gurzeler, L.A., Leibundgut, M., Thiel, V., Muhlemann, O., and Ban, N. (2020). SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat Struct Mol Biol *27*, 959-966. 10.1038/s41594-020-0511-8.

30. Finkel, Y., Gluck, A., Nachshon, A., Winkler, R., Fisher, T., Rozman, B., Mizrahi, O., Lubelsky, Y., Zuckerman, B., Slobodin, B., et al. (2021). SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature *594*, 240-245. 10.1038/s41586-021-03610-3.

31. Thoms, M., Buschauer, R., Ameismeier, M., Koepke, L., Denk, T., Hirschenberger, M., Kratzat, H., Hayn, M., Mackens-Kiani, T., Cheng, J., et al. (2020). Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science *369*, 1249-1255. 10.1126/science.abc8665.

32. Hale, B.G., Randall, R.E., Ortin, J., and Jackson, D. (2008). The multifunctional NS1 protein of influenza A viruses. J Gen Virol *89*, 2359-2376. 10.1099/vir.0.2008/004606-0.

1074   33.   Nemeroff, M.E., Barabino, S.M., Li, Y., Keller, W., and Krug, R.M. (1998). Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell *1*, 991-1000. 10.1016/s1097-2765(00)80099-4.

1078   34.   Beloso, A., Martinez, C., Valcarcel, J., Santaren, J.F., and Ortin, J. (1992). Degradation of cellular mRNA during influenza virus infection: its possible role in protein synthesis shutoff. J Gen Virol *73 (Pt 3)*, 575-581. 10.1099/0022-1317-73-3-575.

1081   35.   Plotch, S.J., Bouloy, M., Ulmanen, I., and Krug, R.M. (1981). A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell *23*, 847-858. 10.1016/0092-8674(81)90449-9.

1085   36.   Beaton, A.R., and Krug, R.M. (1981). Selected host cell capped RNA fragments prime influenza viral RNA transcription in vivo. Nucleic Acids Res *9*, 4423-4436. 10.1093/nar/9.17.4423.

1088   37.   Joachims, M., Van Breugel, P.C., and Lloyd, R.E. (1999). Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol *73*, 718-727. 10.1128/JVI.73.1.718-727.1999.

1091   38.   Haghighat, A., Svitkin, Y., Novoa, I., Kuechler, E., Skern, T., and Sonenberg, N. (1996). The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase. J Virol *70*, 8444-8450. 10.1128/JVI.70.12.8444-8450.1996.

1094   39.   Gradi, A., Svitkin, Y.V., Imataka, H., and Sonenberg, N. (1998). Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc Natl Acad Sci U S A *95*, 11089-11094. 10.1073/pnas.95.19.11089.

1098   40.   Rajani, K.R., Pettit Kneller, E.L., McKenzie, M.O., Horita, D.A., Chou, J.W., and Lyles, D.S. (2012). Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription. PLoS Pathog *8*, e1002929. 10.1371/journal.ppat.1002929.

1102   41.   Pan, W., Song, D., He, W., Lu, H., Lan, Y., Tong, J., Gao, F., and Zhao, K. (2017). The matrix protein of vesicular stomatitis virus inhibits host-directed transcription of target genes via interaction with the TFIIH subunit p8. Vet Microbiol *208*, 82-88. 10.1016/j.vetmic.2017.07.020.

1106   42.   Faria, P.A., Chakraborty, P., Levay, A., Barber, G.N., Ezelle, H.J., Enninga, J., Arana, C., van Deursen, J., and Fontoura, B.M. (2005). VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell *17*, 93-102. 10.1016/j.molcel.2004.11.023.

1109   43.   Duan, Z., Deng, S., Ji, X., Zhao, J., Yuan, C., and Gao, H. (2019). Nuclear localization of Newcastle disease virus matrix protein promotes virus replication by affecting viral RNA synthesis and transcription and inhibiting host cell transcription. Vet Res *50*, 22. 10.1186/s13567-019-0640-4.

1113   44.   Gainey, M.D., Dillon, P.J., Clark, K.M., Manuse, M.J., and Parks, G.D. (2008). Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation. J Virol *82*, 828-839. 10.1128/JVI.02023-07.

1116   45.   Schmidt, E.K., Clavarino, G., Ceppi, M., and Pierre, P. (2009). SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods *6*, 275-277. 10.1038/nmeth.1314.

1119   46.   Younis, I., Berg, M., Kaida, D., Dittmar, K., Wang, C., and Dreyfuss, G. (2010). Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol Cell Biol *30*, 1718-1728. 10.1128/MCB.01301-09.

1122   47.   Neidermyer, W.J., Jr., and Whelan, S.P.J. (2019). Global analysis of polysome-associated mRNA in vesicular stomatitis virus infected cells. PLoS Pathog *15*, e1007875. 10.1371/journal.ppat.1007875.

48. Bensaude, O., Barbosa, I., Morillo, L., Dikstein, R., and Le Hir, H. (2024). Exon-junction complex association with stalled ribosomes and slow translation-independent disassembly. Nat Commun *15*, 4209. 10.1038/s41467-024-48371-5.

49. Wignall-Fleming, E.B., Hughes, D.J., Vattipally, S., Modha, S., Goodbourn, S., Davison, A.J., and Randall, R.E. (2019). Analysis of Paramyxovirus Transcription and Replication by High-Throughput Sequencing. J Virol *93*. 10.1128/JVI.00571-19.

50. Genoyer, E., Kulej, K., Hung, C.T., Thibault, P.A., Azarm, K., Takimoto, T., Garcia, B.A., Lee, B., Lakdawala, S., Weitzman, M.D., and Lopez, C.B. (2020). The Viral Polymerase Complex Mediates the Interaction of Viral Ribonucleoprotein Complexes with Recycling Endosomes during Sendai Virus Assembly. mBio *11*. 10.1128/mBio.02028-20.

51. Fontaine, K.A., Leon, K.E., Khalid, M.M., Tomar, S., Jimenez-Morales, D., Dunlap, M., Kaye, J.A., Shah, P.S., Finkbeiner, S., Krogan, N.J., and Ott, M. (2018). The Cellular NMD Pathway Restricts Zika Virus Infection and Is Targeted by the Viral Capsid Protein. mBio *9*. 10.1128/mBio.02126-18.

52. Ramage, H.R., Kumar, G.R., Verschueren, E., Johnson, J.R., Von Dollen, J., Johnson, T., Newton, B., Shah, P., Horner, J., Krogan, N.J., and Ott, M. (2015). A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol Cell *57*, 329-340. 10.1016/j.molcel.2014.12.028.

53. Li, M., Johnson, J.R., Truong, B., Kim, G., Weinbren, N., Dittmar, M., Shah, P.S., Von Dollen, J., Newton, B.W., Jang, G.M., et al. (2019). Identification of antiviral roles for the exon-junction complex and nonsense-mediated decay in flaviviral infection. Nat Microbiol *4*, 985-995. 10.1038/s41564-019-0375-z.

54. Ren, X., Yu, Y., Li, H., Huang, J., Zhou, A., Liu, S., Hu, P., Li, B., Qi, W., and Liao, M. (2019). Avian Influenza A Virus Polymerase Recruits Cellular RNA Helicase eIF4A3 to Promote Viral mRNA Splicing and Spliced mRNA Nuclear Export. Front Microbiol *10*, 1625. 10.3389/fmicb.2019.01625.

55. Boehm, V., and Gehring, N.H. (2016). Exon Junction Complexes: Supervising the Gene Expression Assembly Line. Trends Genet *32*, 724-735. 10.1016/j.tig.2016.09.003.

56. Woodward, L.A., Mabin, J.W., Gangras, P., and Singh, G. (2017). The exon junction complex: a lifelong guardian of mRNA fate. Wiley Interdiscip Rev RNA *8*. 10.1002/wrna.1411.

57. Schlautmann, L.P., and Gehring, N.H. (2020). A Day in the Life of the Exon Junction Complex. Biomolecules *10*. 10.3390/biom10060866.

58. Leon, K., and Ott, M. (2021). An 'Arms Race' between the Nonsense-mediated mRNA Decay Pathway and Viral Infections. Semin Cell Dev Biol *111*, 101-107. 10.1016/j.semcdb.2020.05.018.

59. Popp, M.W., Cho, H., and Maquat, L.E. (2020). Viral subversion of nonsense-mediated mRNA decay. RNA *26*, 1509-1518. 10.1261/rna.076687.120.

60. Tidu, A., Janvier, A., Schaeffer, L., Sosnowski, P., Kuhn, L., Hammann, P., Westhof, E., Eriani, G., and Martin, F. (2020). The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation. RNA *27*, 253-264. 10.1261/rna.078121.120.

61. Zhang, K., Miorin, L., Makio, T., Dehghan, I., Gao, S., Xie, Y., Zhong, H., Esparza, M., Kehrer, T., Kumar, A., et al. (2021). Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci Adv *7*. 10.1126/sciadv.abe7386.

62. Katze, M.G., DeCorato, D., and Krug, R.M. (1986). Cellular mRNA translation is blocked at both initiation and elongation after infection by influenza virus or adenovirus. J Virol *60*, 1027-1039. 10.1128/JVI.60.3.1027-1039.1986.

63. Garfinkel, M.S., and Katze, M.G. (1993). Translational control by influenza virus. Selective translation is mediated by sequences within the viral mRNA 5'-untranslated region. J Biol Chem *268*, 22223-22226.

1177   64.   Fortes, P., Beloso, A., and Ortin, J. (1994). Influenza virus NS1 protein inhibits pre-
1178   mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J *13*, 704-712.
1179   10.1002/j.1460-2075.1994.tb06310.x.
1180   65.   Qiu, Y., and Krug, R.M. (1994). The influenza virus NS1 protein is a poly(A)-binding
1181   protein that inhibits nuclear export of mRNAs containing poly(A). J Virol *68*, 2425-
1182   2432. 10.1128/JVI.68.4.2425-2432.1994.
1183   66.   Satterly, N., Tsai, P.L., van Deursen, J., Nussenzveig, D.R., Wang, Y., Faria, P.A.,
1184   Levay, A., Levy, D.E., and Fontoura, B.M. (2007). Influenza virus targets the mRNA
1185   export machinery and the nuclear pore complex. Proc Natl Acad Sci U S A *104*, 1853-
1186   1858. 10.1073/pnas.0610977104.
1187   67.   Beaty, S.M., Park, A., Won, S.T., Hong, P., Lyons, M., Vigant, F., Freiberg, A.N.,
1188   tenOever, B.R., Duprex, W.P., and Lee, B. (2017). Efficient and Robust
1189   Paramyxoviridae Reverse Genetics Systems. mSphere *2*. 10.1128/mSphere.00376-16.
1190   68.   Yun, T., Park, A., Hill, T.E., Pernet, O., Beaty, S.M., Juelich, T.L., Smith, J.K., Zhang,
1191   L., Wang, Y.E., Vigant, F., et al. (2015). Efficient reverse genetics reveals genetic
1192   determinants of budding and fusogenic differences between Nipah and Hendra viruses
1193   and enables real-time monitoring of viral spread in small animal models of henipavirus
1194   infection. J Virol *89*, 1242-1253. 10.1128/JVI.02583-14.
1195
1196

Figure 1.

Figure 1. Puromycylation of newly synthesized protein in paramyxovirus-infected or viral proteins transfected HEK-293T cells. (A) HEK-293Ts were treated with either mock or cycloheximide (CHX) at 200 µg/ml for 5 hours, followed by a 20-minute treatment with either mock or puromycin at 10 µg/ml. After the puromycin pulse, cells were washed with PBS and re-fed with complete media. Lysates were analyzed by immunoblotting, and newly synthesized (puromycylated) proteins were probed using an anti-puromycin antibody. (B-C) HEK-293Ts were inoculated with mock, HPIV3, or Cedar virus and puromycin pulsed at indicated time points. Lysates were immunoblotted to probe puromycylated proteins. The expression of HPIV3 nucleocapsid (N) and EGFP served as controls for HPIV3 and Cedar infections, respectively. (D) Flag-fused viral proteins from individual HPIV3 genes or an empty vector (EV) were expressed in HEK-293T cells for 48 hours, followed by puromycylation and immunoblot analysis to detect puromycylated proteins. Expression of viral proteins was detected with an anti-FLAG antibody, with molecular weights indicated by black arrows. F0: F precursor. F1: cleaved F. (E-F) HEK-293T cells were expressed designated FLAG-fused matrix (M) proteins from HPIV3 or NiV, including wild-type (WT) and mutants (Bp12: NLS mutant, LL: NES mutant), along with EV control for 24 or 48 hrs. Following puromycylation, immunoblotting was conducted to determine the puromycylated protein and flag-fused matrix. (G) HPIV3 or HPIV3ΔM virus-infected HEK-293Ts were analyzed by immunoblotting after puromycylation at 24- and 48-hrs post-infection to detect puromycylated protein and HPIV3

viral proteins. HPIVP3-N and HPIV3-M served as infection control. The numbers below each column indicate the relative protein abundance measured by densitometry and normalized as described in the Materials and Methods.

Figure 2.

Figure 2. Effects of paramyxoviral-matrix on Nipah-NPL replicon and the expression of cellular splicing-dependent luciferase. (A) HEK-293Ts were transfected with either NiV or HPIV3 matrix for 24 h. Following transfection, cells were inoculated with NiV-NPL replicon virus-like particles (VPL) and incubated for an additional 48 hours. Relative luciferase activity was measured using the Nano-Glo HiBiT system (upper panel). Puromycin-pulsed cells were analyzed by immunoblotting to assess protein expression levels (lower panel). (B-F) Total RNA was extracted from cells treated as in (A) and subjected to RT-qPCR. Relative viral transcript quantity (RQ) was normalized to GAPDH expression. (G) Luciferase activity (RLU) in HEK-293Ts co-transfected with paramyxoviral matrix protein and intron-containing luciferase reporters (Luc-I) for 24 h. RLU was detected using the ONE-Glo system. Expression

of FLAG-fused matrixes was analyzed by immunoblotting. Relative luciferase expressions were normalized to EV. (H) A standard curve showing RLUs versus transcripts in HEK-293Ts transfected with varying amounts of Luc-I reporter (250 ng to 0.98 ng, 4-fold serial dilution). RLUs were measured using the ONE-Glo system, and transcript levels relative to 18S rRNA were determined by RT-qPCR. Relative levels were normalized to cells transfected with the maximum amount of Luc-I reporter. (I) Relative levels of RLU and transcripts in HEK-293Ts co-transfected with designated viral matrix and Luc-I reporter. RLUs and transcripts were measured as described in (H). With relative levels normalized to EV. Symbols are data points from biological triplicates. Bar represents the mean $\pm$ SD. Statistical significance was determined by one-way ANOVA with Dunnett multiple comparison test. ** P <0.01; **** P <0.0001; ns, not significant.

Figure 3.

Figure 3. Polysome profile and viral transcript distribution in HPIV3 and HPIV3ΔM infected cells. (A) Polysome profiles of mock-infected (black), HPIV3 infected (blue), or HPIV3ΔM infected (red) HEK-293Ts at 48 hrs post-infection (hpi). HEK-293Ts were infected with HPIV3 or HPIV3ΔM at MOI of 3. Cytoplasmic extracts were prepared at 48 hpi and subjected to sedimentation through a 10-50% sucrose gradient. Absorbance at 254 nm was continuously monitored, and 0.6 ml fractions were collected. Distribution of fragments mapping to (B) human and HPIV3 or (C) human and HPIV3ΔM genome across the sucrose gradient fractions 7 to 16 at 48 hpi. (D-E) Distribution of viral transcript among the seven viral genes of either HPIV3 or HPIV3ΔM infected HEK-293Ts at 48 hpi. The percentage of

mapped viral transcripts was quantified using the transcripts per kilobase Million (TPM) metric to normalize for gene length and library size. (F) Comparative analysis of ribosome association efficiency of viral transcripts in HPIV3 and HPIV3ΔM infected cells. Statistical significance was analyzed by Wilcoxon test. * P <0.05.

Figure 4.

**Figure 4. Effects of HPIV3 matrix on the relative abundance of individual cellular mRNAs between monosome and polysome.** (A) Scatter plots of transcripts per kilobase Million (TPM) for cellular mRNA transcripts in monosome fraction at 48 hpi. The x-axis graphed unique cellular mRNAs from mock-infected cells, and the y-axis depicted the corresponding TPM values for each mRNA in either mock-infected (gray circles), HPIV3-infected (blue circles) or HPIV3ΔM infected cells (red triangles). (B) Density plots of the log2 fold change in TPM for cellular mRNAs between virus-infected (HPIV3 or HPIV3ΔM) and mock-infected cells in monosome fraction. (C) Scatter plots of TPMs for cellular mRNA transcript in polysome fraction, presented as in A. (D) Density plots of the log 2fold change in TPM in polysome fraction, presented as in B.

Figure 5.

Figure 5. Interactions between Paramyxovirus matrixes and the core components of exon junction complex. (A) Protein complexes enriched in CORUM protein database from matrix interactome identified by MudPIT analysis. Adjusted P-value indicated the significance of the enriched protein complex. (B) HEK-293Ts overexpressing the indicated FLAG-tagged matrix proteins were Immunoprecipitated (+/- RNase) with Anti-FLAG M2 affinity gel after 48 hrs post-transfection. Matrix-bound proteins were analyzed by immunoblotting and endogenous levels of eIF4AIII, Y14, and MAGOH were detected by designated Abs. The amount of input was 5% of total IP lysates. (C) HEK-293Ts were subjected to HA-tag immunoprecipitation following inoculation with HPIV3 containing none or HA-tagged matrix at 0.01 m.o.i at 48 hrs post-infection. (D) Nuclear and cytoplasmic fractions from cells expressing specified FLAG-tagged matrix proteins were subjected to FLAG immunoprecipitation. Subsequent immunoblotting identified interacting proteins. Values below the blots represent the intensity ratios of eIF4AIII, Y14, and MAGOH from cytoplasm to nucleus. β-Tubulin and Lamin A/C served as cytoplasmic and nuclear fraction markers, respectively. IP, immunoprecipitation. IB, immunoblot.

Figure 6.

Figure 6. Subcellular localization of core EJC in HPIV3 infected HeLa cells. (A-B) Immunoblotting analysis of whole cell lysates, cytoplasmic, and nuclear fractions from HPIV3-infected HeLa cells at 12- and 24-hours post-infection (hpi). The levels of eIF4AIII, Y14, and MAGOH were examined, with β-tubulin and Lamin A/C serving as markers for the purity of cytoplasmic and nuclear fractions, respectively. The ratios below the blots indicate the relative intensities of eIF4AIII, Y14, and MAGOH from the cytoplasm to the nucleus. (C-E) XYZ planes of 3D confocal micrographs depicted HeLa cells at 24 hours post-infection with HPIV3 at m.o.i of 5. Cells were fixed and stained with (C) anti-eIF4AIII, (D) anti-Y14, or (E) anti-MAGOH antibodies (red), and anti-HPIV3-M antibody (cyan) to label the viral matrix protein. Nuclei were counterstained with Hoechst (blue), and GFP fluorescence indicates HPIV3 infection. Enlarged orthogonal projections of the infected cells (white dashed line) are shown on the right, displaying the EJC protein, HPIV3-M, and the merged channels. Scale bars represent 20 μm. (F) Left: HeLa cells infected with either HPIV3 or HPIV3ΔM at an m.o.i. of 5 were fixed at 24 hours post-infection and stained with anti-eIF4AIII (red), anti-HPIV3-M antibodies

(cyan), Hoechst for nuclei (blue), and GFP fluorescence indicates HPIV3 infection. Representative fields of cells for each condition are shown. Right panel: Quantification of cytoplasmic/nuclear eIF4AIll intensity (C: N) ratios was performed on 30 individual cells, as described in Materials and Methods. Statistical significance was analyzed by unpaired t-test. **** P <0.0001.

Figure 7.

Figure 7. Effects of paramyxoviral-matrix on Nipah-NPL replicon in eIF4AIII knockdown cells. (A) HEK-293T cells were co-transfected with either control siRNA (siNC) or siRNA pool targeting eIF4AIII (sieIF4AIII) along with an empty vector (EV) or plasmids NiV-M or HPIV3-M 24 h. Following transfection, cells were inoculated with rNiV-NPL replicon virus-like particles (VPL) and incubated for an additional 48 hours. Relative luciferase activity was measured using the Nano-Glo HiBiT system (upper panel). Puromycin-pulsed cells were analyzed by immunoblotting to assess protein expression levels (lower panel). (B-F) Total RNA was extracted from cells treated as in (A) and subjected to RT-qPCR. Relative viral transcript quantity (RQ) was normalized to GAPDH expression. Symbols are data points from biological triplicates. Bar represents the mean ± SD. Statistical significance was determined by one-way ANOVA with Dunnett multiple comparison test. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant.

Figure 8.

Figure 8. Effects of the exon junction complex on Paramyxovirus, Influenza A, Enterovirus D68, and SARS-CoV2 replication. HEK-293T cells were transfected with siRNA pools targeting eIF4A3, Y14, MAGOH, or non-targeting control siRNAs (NC), respectively. At 48 hrs post-transfection, cells were inoculated with the designated virus (A) HPIV3, (B) Cedar, (C) MuV, (D) NDV, (E) Influenza A (A/WSN/1933), (F) Enterovirus D68, and (G) SARA-CoV2 at a multiplicity of infection (m.o.i.) of 0.01. The titers of infectious

supernatants were determined on Vero-CCL81 cells using a 10-fold serial dilution at the indicated time points. For each virus, the expression levels of endogenous eIF4AIII, Y14, and MAGOH, along with infection control for viral protein or EGFP reporter, were analyzed by immunoblotting; results shown beside each panel confirm the knockdown of target proteins and validate virus infection. Symbols represent the data points from biological triplicates. Bars represent the mean of the triplicates. Statistical significance was determined by two-way ANOVA with Dunnett multiple comparison test. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$; ns, not significant. Immunoblottings are shown beside each to determine the knockdown of target proteins and controls for virus infection.

Figure S1.

(A)

```
²⁴³VRRAGKYYSVDYCRRKIDRM  NiV-M
²⁴³KRKVGRMYSVEYCKQKIEKM  HPIV3-M
²⁴³AAAVGRMYSVEYCAAAIEKM  Mbp1/2
¹⁰¹SHPQDLLEELCSLKVTVRRT  NiV-M
¹⁰¹GNDQELLQAATKLDIEVRRT  HPIV3-M
¹⁰¹GNDQEAAQAATKLDIEVRRT  L106A/107A
```

(B)

(C)

Figure S1. Mutagenesis studies of nuclear localization signals (NLSs) and nuclear export signals (NESs) in GFP fused HPIV3-M and NiV-M. (A) Positively charged amino acid residues in the bipartite NLSs or key leucine residues in the potential NESs were mutated to alanine. (B) HeLa cells expressing either wild-type (WT), NLS mutant (Mbp1/2), or NES mutant (L106A L107A) forms of GFP-fused HPIV3-M and NiV-M were fixed and stained with Hoechst to visualize nuclei. Representative fields of cells expressing each construct are shown. Scale bars represent 20 μm (C) Quantification of the cytoplasmic/nuclear GFP intensity (C: N) ratios for 30–50 individual cells was analyzed for each mutant, as described in the Materials and Methods. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparison test. **** $P < 0.0001$.

Figure S2.

Figure S2. Effects of HPIV3 infection and matrix protein on host translational profile. (A) Polysome profiles of mock-infected (black), HPIV3 infected (blue), or HPIV3-M transfected (red) HEK-293Ts at 48 hrs post-infection. HEK-293Ts were infected with HPIV3 (MOI of 5) or transfected with matrix for 48 hrs and cytoplasmic extracts were prepared for polysome profiling. Cytoplasmic extracts were sedimented through a 10–50% sucrose gradient and 0.6 ml fractions were collected while continuously measuring absorbance at λ = 254nm. (B) Proteins were TCA precipitated from the collected fraction with equal volume and analyzed by immunoblotting to determine the sedimentation of S6, L7a, eIF4AIII, Y14, MAGOH, and HPIV3-M with ribosomal subunits, monosomes, or polysomes. (C-D) Densitometric quantification of the indicated proteins (S6 and L7a) across 16 fractions from (B). The y-axis shows the percentage of the total integrated intensity (% of Total Int) for each protein in the indicated condition: mock infection (black), HPIV3 infection (blue), and HPIV3 matrix protein expression (red).

Figure S3.

Figure S3. Nuclear-cytoplasmic trafficking of HPIV3 matrix protein (HPIV3-M) during infection. (A) HeLa cells infected with HPIV3 at m.o.i of 5 and then incubated with fresh growth medium for up to 24 hrs. At 12, 16, 20, and 24 hours of post-infection, cells were fixed and counterstained with anti-HPIV3-M antibody (red) to label viral matrix protein, and nuclei were stained with Hoechst (blue). Representative fields of cells at each time point are shown. Scale bars represent 20 μm (B) Quantification of cytoplasmic/nuclear HPIV3-M intensity (C: N) ratios was performed on 30–50 individual cells, as described in the Materials and Methods. Statistical significance was analyzed by one-way ANOVA with Dunnett. **** $P < 0.0001$; ns, not significant.

Figure S4.

Figure S4. Effects of the exon junction complex on Paramyxovirus infection. HEK-293T cells were transfected with siRNA pools targeting eIF4A3, Y14, MAGOH, or non-targeting control siRNAs (NC), respectively. At 48 hrs post-transfection, cells were inoculated with the designated virus (A) HPIV3, (B) Cedar, (C) MuV, and (D) NDV at a multiplicity of infection (m.o.i.) of 0.01. The number of GFP-positive cells in each well was acquired at the indicated time points by Celigo imaging cytometer (Nexcelom). Relative fold changes (FC) in GFP-positive cells per well were then calculated. Symbols represent the data points from biological triplicates. Bars represent the mean of the triplicates. Statistical significance was determined by two-way ANOVA with Dunnett multiple comparison test. * P <0.05; ** P <0.01; *** P <0.001; **** P <0.0001; ns, not significant.

# Figure S5.

Figure S5. Subcellular localization of eIF4AIll in HeLa cells expressing GFP fused HPIV3 matrixes. Left panel HeLa cells expressing either wild-type (WT), NLS mutant (Nbp1/2), or NES mutant (L106A L107A) forms of GFP-fused HPIV3-M and NiV-M were fixed and stained with anti-eIF4AIII (red) and Hoechst for nuclei (blue), and GFP fluorescence indicates M expression. Representative fields of cells for each condition are shown. Scale bars represent 20 μm. Right panel: Quantification of cytoplasmic/nuclear eIF4AIll intensity (C: N) ratios was performed on 30 individual cells, as described in Materials and Methods. Statistical significance was analyzed by one-way ANOVA with Dunnett multiple comparison test. **** *P* <0.0001; ns, not significant.

## Figure S6.

Figure S6. Effects of HPIV3 infection on NMD activity. HEK-293T cells infected with HPIV3 at m.o.i of 0.01 and analyzed at 24 and 48 hours of post-infection. Endogenous targets of the NMD mRNA surveillance pathway, SC35, GABARAPL1, ASNS, and CARS were analyzed by quantitative RT-PCR. Relative quantification (Gene/GAPDH) is normalized to uninfected controls. Symbols are data points from biological triplicates. Bar represents the mean ± SD. Statistical significance was determined by one-way ANOVA with Dunnett multiple comparison test. * P <0.05; **** P <0.0001; ns, not significant.

Figure S7.

Figure S7. Effects of HPIV3 matrix on NMD activity. HEK-293T cells were transfected with the indicated protein and analyzed at 24 and 48 hrs post-transfection. Endogenous targets of the NMD mRNA surveillance pathway, SC35, GABARAPL1, ASNS, and CARS were analyzed by quantitative RT-PCR. Relative quantification (Gene/GAPDH) is normalized to uninfected controls. Symbols are data points from biological triplicates. Bar represents the mean ± SD. Statistical significance was determined by two-way ANOVA with Bonferroni's multiple comparisons test. ns, not significant.

Figure S8.

Figure S8. Recovery of rHPIV3ΔM-mCherry and rHPIV3ΔM viruses in BSR-T7 cells. Representative images from the rescue of (A) rHPIV3ΔM-mCherry and (B) rHPIV3ΔM at day 3 of post-transfection in BSR-T7 cells. Images were captured by EVOS m5000.

Table S1.

Table S1: qPCR primers, related to Star Methods.

Gene	Forward Primer (5' to 3')	Reverse Primer (5' to 3')
SC35	CGGTGTCCTCTTAAGAAAATGATGTA	CTGCTACACAACTGCGCCT
ASNS	GGAAGACAGCCCCGATTTACT	AGCACGAACTGTTGTAATGTCA
CARS	CCATGCAGACTCCACCTTTAC	GCAATACCACGTCACCTTTTTC
GABARAPL1	GGCCAGTTCTACTTCTTAATCCGG	AGGTGCTCCCATCTGCTGGG
NiV_N	CGTGGTTATCTTGAGCCTATGT	TCCCAGTCTATTTGCCATGTT
NiV_P	GGAGCATCGAGAGGTCAATAAG	GGACTTTGGCATCGGAGTT
NiV_L	GCGTCTCAGAGGGTAAACATAG	GAGTACACTCCCTGCAAACTTA
NiV_Genome	TCTCCCAGAGTCTATCAGTAAGG	TCCCAGTCTATTTGCCATGTT
NiV_Antigenome	AACTTAGGAACCAAGACAAACAC	CTAGCCGCCTCTTCAAAGATA
18S	GTAACCCGTTGAACCCCATT	CCATCCAATCGGTAGTAGCG
GAPDH	CCACATCGCTCAGACACCAT	AAAAGCAGCCCTGGTGACC
Luciferase	GATCCTCAACGTGCAAAAGAAGC	TCACGAAGGTGTACATGCTTTGG